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ABSTRACT
Regulation of the Amyloid Precursor Protein by Prostaglandin J2, A
Mediator of Inflammation: Relevance to Alzheimer’s Disease
By
Teneka Jean-Louis
Advisor: Dr. Maria E. Figueiredo-Pereira

Inflammation plays a major role in Alzheimer’s disease (AD). Investigating how specific
mediators of inflammation contribute to neurodegeneration in AD is crucial. Our studies focused
on cyclooxygenases, which are key enzymes in inflammation and highly relevant to AD.
Cyclooxygenases (COX -1, constitutive; COX-2, inducible) have emerged as important
determinants of AD pathogenesis and progression. COX-2 is highly induced in AD, correlating
with AD severity, and COX-1 is also involved in AD. Cyclooxygenases are the rate-limiting
enzymes that convert arachidonic acid into prostaglandins (PGs), the principal mediators of CNS
neuroinflammation.
The overall GOAL of these studies was to address the mechanisms by which the
neurotoxic prostaglandin J2 (PGJ2) contributes to the pathophysiology of AD.
In rodents, stroke (cerebral ischemia) and traumatic brain injury (TBI) elevate PGJ2
levels in the brain to concentrations similar to those shown to be neurotoxic in vitro. Stroke and
TBI increase the long-term risk for AD through mechanisms that are unknown. Thus, the studies
presented in this dissertation specifically investigated mechanisms induced by PGJ2 relevant to
AD pathology. To achieve our GOAL we carried-out two specific aims:
v

Specific aim 1: Determine the effects of PGJ2 on processing of the amyloid
precursor protein (APP) in neuronal cells (Chapter 2).
Senile plaques (SP) are pathological hallmarks of AD. The main component of SPs is Aβ,
generated via APP cleavage by β and γ-secretases in the amyloidogenic pathway. Alternatively,
APP processing by α and γ-secretases in the non-amyloidogenic pathway prevents Aβ formation.
The upstream events that regulate APP processing by the amyloidogenic and non-amyloidogenic
pathways require further investigation.
We addressed mechanisms by which PGJ2 affects APP processing in rat primary
neuronal cultures and in human SY5Y neuroblastoma cells overexpressing APP (APP-SY5Y).
We found that PGJ2-treatment:
(1) Increased the overall levels of protein O-GlcNAcylation, a form of O-glycosylation
where O-linked β-N-acetylglucosamine (O-GlcNAc) is linked to serine and threonine residues in
nucleocytoplasmic protein domains. O-GlcNAcylation is known to occur on APP and to protect
proteins from proteasomal degradation.
(2) Promoted APP processing by α and β-secretases.
Overall, these results suggest that by increasing protein O-GlcNAcylation levels, PGJ2
renders mature APP less prone to proteasomal degradation, thus shunting APP toward processing
by α and β-secretases. These PGJ2-induced APP glycosylation and proteolytic mechanisms that
generate various secreted N-terminal APP fragments, should be targeted in conjunction with Aβ
formation to prevent/treat AD pathophysiology linked to neuroinflammation.
Specific AIM 2: Investigate the effects of PGJ2 on the progression of molecular and
behavioral pathology in the 3xTg-AD mouse model of AD (Chapter 3).

vi

Since neuroinflammation promotes AD pathogenesis and progression, we investigated
whether PGJ2 hippocampal microinfusions would accelerate AD pathology in 3xTg-AD male
mice. We targeted the hippocampus because it is the brain region responsible for memory
consolidation, storage and spatial/working memory.
The 3xTg-AD mice are homozygous for two mutations linked to familial AD (APP
Swedish and presenilin 1 M146V) and one for frontotemporal dementia (FTD) (TAU P301L).
These mice are viable, fertile, and are initially physically and behaviorally normal. Transgene
expression is restricted to the CNS including the hippocampus and cerebral cortex. These 3xTgAD mice are unique in that they develop plaque and tangle pathology. Aβ deposition develops by
3-4 months, LTP impairment by 6 months, and tau hyperphosphorylation by 12-15 month.
To assess the effect of PGJ2 on AD progression, 3xTg-AD male mice were injected with
PGJ2 at five weeks of age, before any pathology developed. The mice received three bilateral
PGJ2 (16.7µg/2µl) injections, into the right and left hippocampal CA1 regions. The mice were
assessed for cognitive behavior throughout the experimental period. At the end of the
experiments, the mice were sacrificed and analyzed by immunohistochemistry to assess changes
in APP (6e10) and tau (HT7), neuronal loss (NeuN), and gliosis (Iba1 and GFAP).
We found that the PGJ2 microinfusions induced premature:
(1) Cognitive impairment manifested by increased working memory errors and decreased
learning.
(2) Elevated Aβ deposition within the hippocampal CA1 cell layer and cerebral cortex. In
addition, we detected a significant rise in Aβ uptake by astrocytes and microglia in these areas.
Conversely, decreased Aβ deposits and decreased glial intracellular amyloid deposition was
observed in the stratum lacunosum moleculare (SLM) of CA1 and pyramidal cell layer of CA3.
vii

There was no neuronal loss or tau aggregation detected in the hippocampi and cerebral cortices,
as assessed by NeuN immunostaining.
These studies show that PGJ2-microinfusions accelerated AD pathology in vivo in the
3xTg-AD mice via progression of working/spatial memory deficits and increased Aβ deposition.
Conclusion: Targeting prostaglandins such as PGJ2 that mediate neurodegeneration
downstream from cyclooxygenases, is a novel therapeutic strategy that could improve clinical
outcomes with fewer side effects. This global strategy is applicable to AD and other neurological
disorders in which the cyclooxygenase pathway of inflammation plays a critical role.
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CHAPTER I

INTRODUCTION

1. a. Amyloid Precursor Protein: structure, processing, function, and glycosylation
1. b. Prostaglandin J2 and Inflammation

Teneka L Jean-Louis

Department of Biological Sciences,
Hunter College of the City University of New York,
New York, New York 10065
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1. a. AMYLOID PRECURSOR PROTEIN: STRUCTURE, PROCESSING, FUNCTION,
AND GLYCOSYLATION

1. a.1.

Amyloid precursor protein (APP)
The amyloid precursor protein, or APP, is a 100-140kDa type I transmembrane

glycoprotein with most of its structure in the extracellular space. APP plays a critical role in AD
pathology and its Aβ fragment presence in plaques is an established hallmark of the disease. APP
is a member of the family of proteins that includes APP-like-protein 1 (APLP1) and 2 (APLP2)2.
APP is present in most cells, residing in the plasma, endoplasmic reticulum (ER), and
mitochondrial membranes.
1. a.2 APP domains
In humans, the gene encoding for APP is located on the 21st chromosome and spans
240kb3. The APP gene contains
at least 18 exons and alternate
splicing at the 7th, 8th, and 15th
exons generates proteins of
different lengths ranging from
365 to 770 amino acids3;4. The
Fig 1. APP domains. Conserved domains of APP are the E1, E2, and AICD.
Not all forms of APP have the Aβ domain or the Kunitz-type serine protease
inhibitor (KPI)/MRC Ox-2 antigen (Ox) domains. APP770, APP751 forms
contain all the domains listed above. However APP695, the most abundant
APP form in neurons, does not contain the KPI/Ox domains. (Taken from
Reinhard et al 2005)

APP mRNA lacking exons 7 and
8 is the most abundant form in
the brain5. Exons 7 and 8
correspond to the Kunitz-type

serine protease inhibitor (KPI) and to the MRC Ox-2 antigen (Ox) domain, respectively5. The
three main isoforms of APP are the 695, 751 and 770 amino acid long proteins6. APP751 and
2

APP770 are expressed in most tissues and contain a 57 amino acid KPI domain6. The KPI
domain is very similar to a group of proteins which inhibit peptidases and is characterized by a
serine residue within the active site4. APP695 is predominantly expressed in neurons, but lacks
the KPI domain3;4. This finding suggests that RNA splicing in APP is cell type regulated, but the
mechanism and significance of this regulation is poorly understood. Next to the KPI domain is
the Ox domain. This domain is homologous to the Ox-2 membrane glycoprotein responsible for
stimulating T-cell proliferation7;8. As shown in Figure 1, the extracellular region of APP also has
conserved E1 and E2 domains8. The E1 domain consists of a growth-like factor domain (GLFD)
and a copper and zinc binding motif (CuBD). The E2 domain consists of the central APP
domain (CAPPD), a RERMS sequence and a membrane linker domain. The 17-amino acid
RERMS sequence has growth-like, neuronal proliferation, and survival properties, which is
usually associated with the N-terminal region8;9. Next to the linker domain of the E2 region is
the Aβ domain which upon enzymatic cleavage produces the Aβ peptides which accumulate in
the senile plaques detected in AD. The C-terminal or APP intracellular domain (AICD), like its
name implicates, is located on the cytoplasmic side of the plasma membrane region.
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1. a.3

APP Processing
APP is proteolytically

Non amyloidogenic
sAPPα

sAPPα
APP

processed via the following
enzymes: β-secretase (BACE),

C83
AICD

P3

Cytoplasm

γ-secretase, and α-secretase
(Fig. 2). Depending on the

Amyloidogenic
sAPPβ

sAPPβ

location of APP, the
amyloidogenic or non-

C99

AICD

Aβ

Fig 2. APP Processing. APP is processed by secretases either via the
amyloidogenic or non-amyloidogenic pathways. In the amyloidogenic pathway
BACE cleaves APP resulting in a free N-terminal fragment. The second phase of
processing via γ-secretase gives rise to the Aβ and AICD fragments. The nonamyloidogenic pathway initiated with α-secretase cleavage produces a free Nterminal fragment. The second phase of processing with γ-secretase gives rise to
the P3 and AICD fragments.

amyloidogenic pathway is
preferred. Once at the plasma
membrane, APP is cleaved by
α- secretase10. BACE cleavage

of APP can occur throughout the cell in endosomes/lysosomes11;12), trans-Golgi, and
autophagosome compartments13.
Non-amyloidogenic processing begins with α-secretase cleaving within the Aβ domain
between Lys16 and Leu17 of Aβ resulting in a free ectodomain fragment or sAPPα6. The
remaining APP still within the membrane, the C83 fragment, is then cleaved by γ-secretase
within the Aβ domain to produce the P3 peptide and the AICD fragment14.
Amyloidogenic processing begins with BACE cleaving within the Aβ domain resulting in
sAPPβ and the C99 fragment. Further γ-secretase processing of the C99 produces the Aβ
peptides and the C-terminal AICD fragment14. The resulting Aβ fragment is on average 40 amino
acids long, but can range from 38-43 amino acids15. Depending on where γ-secretase cleaves in
the amyloidogenic pathway, the length of the AICD fragment ranges from 57 to 59 amino acids.
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There is another cleavage site mediated by γ-secretase known as the ε site, which generates an
AICD that is 50 amino acids long15. The mechanisms surrounding the transition between the
amyloidogenic and the non-amyloidogenic pathways are not well understood. However, it is
known that BACE competes with α-secretase, and certain stimuli or upstream events may
encourage each of the particular processing pathways.
In addition to the non-amyloidogenic and amyloidogenic pathways, there are several other
pathways that also cleave APP. These non-canonical pathways involve other proteases, and other
secretases16. Caspases can also cleave full-length APP and regulate the production of the AICD
fragment6;17. It is unclear whether caspases cleave the C-terminus following BACE or αsecretase. However, caspases cleave after the aspartate residue 665 (based on APP695 sequence)
within the Aβ domain sequentially with γ-secretase to produce the peptide fragments Jcasp and
C3118. The C31 fragment induces toxicity in rat neuroblastoma cells at high concentrations, and
depends on the presence of C9918. In mouse N2a neuroblastoma cells, caspase activity
predominantly cleaves at the C terminus of APP695 to produce the cytotoxic fragment C3118.
Toxic Aβ40 production via γ-secretase cleavage was dependent upon caspase-2 and -8 activity,
in human neuroglioma H4 cells stably expressing Swedish APP69514;19.
Calpain is also implicated in Aβ production. Calpain regulates cell death in response to high
intracellular calcium concentrations. In neurons, intracellular calcium is very important because
it regulates calcium-dependent channels and neuronal signaling via synaptic transmission. In
human embryonic kidney 293 cells (K269 cell line) transfected with human APP695, Aβ42
production is increased upon calpain inhibition20. In rat cortical neurons, calpain activation
resulted in proteasome impairment and cleavage of TAU protein21. In a mouse fibroblast-like cell
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line (Ltk cells) transfected with human APP695, calpain regulated the redistribution of APP to
the cell surface increasing both BACE and α-secretase cleavage in the process22.
The δ-, η- and meprin pathways have been discovered more recently. Some of the
fragments generated by these pathways have been recently implicated in AD pathogenesis, but
very little is known about their physiological role. The δ-pathway involves asparagine
endopeptidase (AEP or δ-secretase), which preferentially cleaves after asparagine residues after
C- and N-terminal cleavage of APP23. Cleavage results in three soluble fragments which can be
further cleaved by β and γ-secretases16. AEP is located within the lysosome and is responsible
for the clearance of electron dense, membranous materials in the late endosomes and lysosomes.
AEP activity is optimal in acidic conditions which result from excitotoxity, and can contribute to
apoptosis by degrading SET, a DNase inhibitor24;25. AEP is inhibited by cystatin C, a protein
found in the CSF responsible for binding and preventing the oligomerization of Aβ26.
The meprin pathway involves the metalloproteinase meprin β. Meprin β is a type 1
transmembrane protein that is usually present as a dimer at the cell surface27. Meprin β can
cleave APP at three sites giving rise to N-terminal truncated Aβ fragments after γ-secretase
cleavage16. Brain homogenates from AD patients also demonstrated increased levels of meprin β
mRNA levels, as well as increased truncated amyloid fragments (Aβ2-42), indicating its
potential role in AD pathology28.
The η-pathway involves the membrane-bound matrix metalloproteinase MT5-MMP (ηsecretase). η-Secretase cleaves APP between the 504 and 505 residues of APP695, releasing a
soluble truncated ectodomain (APPsη) and a longer C-terminal fragment (CTFη)29. The CTFη is
further cleaved by α and β- secretases to generate an Aη-α peptide and a shorter peptide Aη-β.
The CTFs produced by η-secretase have been observed in dystrophic neurites in an AD mouse
6

model (APP/PS1). MT5-MMP null mice were observed to have reduced levels of C99 in the
hippocampus and cortex as well as reduced amyloidosis, glial reactivity, IL-1β, and increased
LTP preservation, suggesting that this pathway has a potential role in AD pathogenesis30.
Autophagy plays a large role in APP cleavage by either regulating the location of BACE
31

or promoting APP homeostatic turnover32;33.

The 26S proteasome also contributes to APP turnover, and this process is hindered by the
association with Aβ34. Proteasomal inhibition was linked to apoptosis and Aβ accumulation and
aggregation in neurons34.
1. a.4 APP Functions
The role of APP is not completely understood, but it is known that it regulates essential
cellular processes, such as cell survival, neurite outgrowth, synaptogenesis, synaptic plasticity,
and neurogenesis35. During neuronal differentiation, phosphorylated APP is anterogradely
transported to the synaptic terminal where it localizes to growth cones, implicating a role in
neurite outgrowth36. In neuromuscular synapses, the loss of APP leads to a choline transporter
deficit, modifying synapse function37.
The cleaved N-terminal fragment, sAPPα has neuroprotective effects on cultured
neurons. Once released, sAPPα protects cultured neurons from stressful conditions such as
oxygen-glucose deprivation and excitotoxicity, by manipulating calcium currents38.
APP was linked to calcium flux in neurons, and as such mediates synaptic transmission
and plasticity, mitochondrial metabolism, and cell viability15. Accordingly, primary hippocampal
neurons from transgenic mice expression APP with the Swedish mutation (mutations in codons
670 and 671 of APP770, G to T and A to C, respectively39) displayed an increase in calcium
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fluctuation frequencies38. The AICD fragment is also linked to cytosolic calcium regulation via
G-protein G0 activation40.
Based on its structural homology to Notch, APP was shown to contribute to cell adhesion via
its extracellular domain14. The N-terminal region of APP associates with various extracellular
proteins8. Its E1 and E2 domains bind to the extracellular matrix proteins heparan sulfate
proteoglycans3;14 as well as self-associates with other APP proteins41. Fibrillar Aβ was shown to
bind to full length APP and induce cell death, possibly by triggering a conformational change in
APP42.
1. a.5. APP post-translational modification: Glycosylation
Glycosylation is considered one of the most abundant forms of post-translational
mediation in tissues43. Protein glycosylation is essential for cell function for it plays a role in
many processes such as immunity44;45, protein folding and stability46;47, sorting48, and signal
transduction49;50.
There are two main forms of glycosylation and the way it occurs is location dependent:
(1) In the cytosol and nucleus, proteins can be post-translationally modified with one βN-acetylglucosamine (O-GlcNac) by O-GlcNAc transferase (OGT)51;52.
(2) In the lumen of ER and Golgi, N-acetylgalactosamine (O-GalNAc) oligosaccharide
chains are added to a specific amino acid residue53. Glycosylation that occurs in the ER is known
as N-glycosylation and has oligosaccharides branching from an asparagine residue. Inside the
lumen of the Golgi, proteins are O-glycosylated with oligosaccharides branching from either a
serine or threonine residue54.
Full length APP is glycosylated in the lumen of the ER and Golgi as well as in the
cytoplasm55-57. Consequently, the immature form of APP is N-glycosylated and its mature form

8

is N and O-glycosylated58. There are two N-linked glycosylated sites located near the end of the
E2 domain59. Multiple O-linked glycosylation sites have been reported with clusters of sites
located near the Aβ domain and between the E1 and E2 domains59;60. Therefore, multiple forms
of full length APP can be detected due to varying amounts of O-glycosylation61. Although up for
debate, studies have shown mature APP to be preferentially cleaved by secretases58;62. It is
unknown if other proteases preferentially cleave mature APP as well. However, APP is heavily
trafficked throughout the cell and cleavage can occur inside the endocytosis, recycling, and
within trans-Golgi vesicles63-65.
The glycosylation of proteins is regulated by glucose metabolism51. AD patients are
shown to have impaired brain glucose metabolism66. Studies have shown Type 2 diabetes to
elevate Aβ levels, suggesting that impaired glucose metabolism could promote AD
pathology67;68. Diabetic patients are also twice as likely to develop AD69-71, which may lead the
way for new therapeutic strategies for AD72. Perturbations in APP O-glycosylation have been
reported in AD as well as impaired trafficking and sorting51;73.
The levels of O-GlcNac, which is highly expressed in the brain, also decrease in AD
patients66. Due to its unique dynamics of glycosylation/deglycosylation, O-GlcNAcylation is
more akin to phosphorylation than ER/Golgi glycosylation. O-GlcNAcylation is known to
prevent protein degradation by the proteasome74, which may increase the likelihood of APP
being cleaved by secretases.
1. a.6. Relevance to AD: Aβ as a biomarker
The Aβ peptide generated by APP processing via the amyloidogenic pathway is a wellestablished hallmark of AD. Under pathological conditions, fibrous Aβ tends to accumulate and
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aggregate into plaques75. Although the direct causes of non-familial AD are unclear, Aβ
accumulation is predicted to play a role in the early pathological stages of non-familial AD76.
Not all Aβ lengths, which range from 38 to 43 amino acids, have the same toxicity15. The
40 and 42 amino acid long Aβ peptides are considered to be the most toxic. Their concentration
ratio (Aβ42 /Aβ40) is proportional to their capacity to promote cell death and dysfunction77. The
Aβ42 peptide is the more toxic of the two, as it is more susceptible to oligomer formation6.
Once produced, Aβ fibers are either secreted from the cell, internalized, or accumulate inside
organelles such as the ER, mitochondria, and Golgi6;78.
Aβ peptides are not restricted to AD, as soluble Aβ peptides are normally detected in the
serum and CSF79. Soluble Aβ is reported to be detected in the medium of healthy human
embryonic kidney 293 cells80, rat primary neural progenitor cells81, as well as the brain and CSF
of healthy individuals82. At picomolar concentrations, Aβ fragment levels are proposed to be
neurotrophic83. The half-life of Aβ fragments within the brain are short (2hrs), with
concentrations changing in response to synaptic activity84. Low levels of Aβ were also reported
to serve as antioxidants, chelating redox metals such as copper, iron and zinc85. These
discoveries suggest that some species of Aβ may be beneficial or necessary for cell development
and function, and that complete removal of Aβ as a therapeutic strategy, should be re-evaluated.
Aβ has also been reported to induce TAU hyperphosphorylation in rat E17/E18
hippocampal neurons86. TAU hyperphosphorylation is one of the first steps that lead to TAU
pathology in AD, and its link to Aβ production may be considered as a trigger for AD pathology.
Higher levels of Aβ in AD brains correlate with BACE levels. Interestingly, BACE upregulation can be induced by Aβ produced via the amyloidogenic pathway, thus driving a
positive feedback loop favoring more APP cleavage by BACE76.
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In conclusion, it is clear that Aβ production is not the only cause of AD pathology, which
most likely includes a combination of stressful events40, such as proteasomal and mitochondrial
dysfunction that can be attributed to aging, stroke, TBI, diabetes, and atherosclerosis87.
1. b. PROSTAGLANDIN J2 (PGJ2) AND INFLAMMATION
Chronic inflammation plays an important role in neurodegeneration and promotes AD
pathology88. Many studies have associated inflammation with higher levels of Aβ, proteasome
impairment89, mitochondrial dysfunction90, and increased cytokines via activated microglia
which exacerbate inflammation88. Mutations in the microglial gene TREM2 encoding an antiinflammatory protein, were implicated in the pathogenesis of AD by two different groups in
201391;92, further supporting the notion that AD is driven by a chronic inflammatory process93.
Cellular stress induced by pathological conditions in the brain such as pathways activated
by infection94;95 and trauma96-98 result in microglia activation. Activated microglia produce
prostaglandins, which are the principal mediators of CNS inflammation. There is a need for
better understanding the role of prostaglandins in AD pathology88;99.
Our studies focus on the role of cyclooxygenases (COXs), in particular their
prostaglandin products, in AD. The cyclooxygenase pathway plays a major role in
neuroinflammation. The brain expresses COX-1 and COX-2 under normal physiological
conditions. However, the expression and activity of COX-2 are largely responsive to adverse
stimuli, such as inflammation and physiologic imbalances100. Notably COX-2 activity is
markedly induced in AD, subsequently leading to neuronal injury101. It is known that
cyclooxygenases and their prostaglandin products are implicated in neurodegeneration in AD102104

. However, current animal and cell models of AD fail to address how prostaglandins redirect
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cellular events to promote neurodegeneration in AD. We specifically address how the neurotoxic
prostaglandin J2 (PGJ2) affects APP processing, which is highly relevant to AD pathology.
1. b.1 Prostaglandin J2 (PGJ2), an endogenous mediator of inflammation
Prostaglandin J2 (PGJ2) is derived by spontaneous dehydration from PGD2, which is
synthesized from arachidonic acid, a polyunsaturated fatty acid released from membrane
phospholipids (Figure 3). PGD2 is one of the most abundant prostaglandins in the brain, thus
PGJ2 is also considered to be quite abundant, like its precursor PGD2105.
Prostaglandins of the J2 series share the common structure of a cyclopentenone ring
containing an electrophilic moiety106. The asterisks in Figure 3 indicate the locations of the
electrophilic carbonyl moiety. Further non-enzymatic dehydration of PGJ2 gives rise to other
species of PGJ2, such as 15d-Δ12,14-PGJ2, that have the α,β unsaturated carbonyl groups
characteristic of the PGJ2 series. These electrophilic carbonyl groups are very reactive and tend
to undergo Michael addition with proteins containing free sulfhydryl groups in cysteine residues.
PGJ2 was shown to covalently bind via Michael addition with molecules such as glutathione,
PPARγ, and other proteins105.
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PGJ2 induces cell survival or cell
death, depending on its concentration105;107.
PGJ2 decreases cell survival and
proliferation via activation of the
p38MAPK and JNK pathways108;109. PGJ2
also inhibits the NFκB pathway110.
Previous studies with neuronal
cultures, showed that PGJ2 induces
apoptosis105;111, decreases mitochondrial
function90;90;112;112, promotes 26S
proteasome disassembly and β5 subunit
Fig. 3 Prostaglandin J2 Synthesis Synthesized from
arachidonic acid, cyclooxygenases process arachidonic acid to
form prostaglandin G2 (PGG2). PPG2 converts to
prostaglandin H2 (PGH2) via dehydration. PGH2 is converted
to prostaglandin D2 (PGD2) via PGD2 synthase. After various
dehydration steps, prostaglandin J2 (PGJ2) and other J2
species form. PGJ2 is highly reactive and can undergo
michael addition with proteins containing a sulfhydryl group.
(Taken from Surh et al. 2006)

inactivation110.
PGJ2 treatment of neuronal cells
raises the levels of COX-2109, interlukin-1α
(IL-1α)113, and prostaglandin E289. These

findings suggest that PGJ2, like other prostaglandins114, could mediate the switch from acute to
chronic inflammation by a positive feedback loop leading to the production of more
prostaglandins and cytokines.
PGJ2 exerts its action by different means: entering cells by diffusion across the plasma
membrane115, or via the prostaglandin transporter (PGT)115;116, or via exosomes117, or by binding
to the DP2 receptor for PGD2118;119, or to the nuclear receptor PPARγ120.
The physiological concentrations of prostaglandins are in the pico to nanomolar range,
but in response to particular cellular stresses their concentrations can increase up to the
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micromolar range at the site of damage110;121. In vivo studies of different stress conditions such as
infection122, temporary focal ischemia, asphyxia cardiac arrest123, and seizures124 have shown
significant increases in the levels of endogenous prostaglandins125.
Table 1 lists the levels of different prostaglandins including PGJ2, detected in vivo within
murine and rat tissues upon exposure to a range of stress conditions. The data support that PGJ2
is highly relevant to neurodegeneration, and can be used as a tool to investigate some of the
pathological effects of inflammation mediated by neuroinflammation.
Table 1- Endogenous Levels of Prostaglandins

PGJ2 is an endogenous product of inflammation that is highly toxic compared to other
prostaglandins, such as A1, D2 and E2126. Furthermore, we and others demonstrated that the
effects of PGJ2 recapitulate many pathological processes that occur in AD, such as (1) inhibits
26S proteasome activity34;127, (2) induces the accumulation/aggregation of ubiquitinated
proteins89 and TAU128; (3) perturbs the cytoskeleton127; (4) up-regulates COX-2129; (5) induces
oxidative stress and impairs mitochondrial function90;112;130. We also demonstrated that
microinfusion of PGJ2 into the substantia nigra/striatum of mice induced a specific and dosedependent degeneration of dopaminergic neurons in the nigrostriatal pathway131. Other showed
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that 15d-PGJ2 is up-regulated in spinal cord motor neurons of patients with ALS130;132, and that
plasma levels of 15d-PGJ2 increased 12-fold and 23-fold in patients following acute stroke133.
These data strongly support the neurotoxic role of PGJ2 not only in AD but also in other
neurodegenerative conditions.
Prostaglandins are produced from arachidonic acid by cyclooxygenases that yield a
variety of products, some with pro-survival others with pro-death effects in the CNS. Although
still controversial, inhibiting cyclooxygenases with non-steroidal anti-inflammatory drugs
(NSAIDs) is being explored as a therapeutic strategy to mitigate chronic inflammation and to
prevent the onset or progression of AD pathology134;135. It is possible that the effectiveness of
NSAIDs is compromised because they block the generation of neuroprotective as well as
neurotoxic prostaglandin products of cyclooxygenases. Thus, understanding how PGJ2 induces
AD-like pathology is critical to the development of novel and more effective therapies to prevent
inflammation-linked neurodegeneration in AD.
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CHAPTER II

The mediator of inflammation prostaglandin J2 promotes protein O-GlcNAcylation raising
α/β-secretase APP processing in neuronal cells: relevance to Alzheimer’s disease
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2.1. ABSTRACT
The amyloid precursor protein (APP) is critical to Alzheimer’s disease (AD), because its
proteolysis generates the amyloid β peptide (Aβ). Regulation of APP processing by α and βsecretases is of special interest, as these proteases prevent or mediate Aβ formation, respectively.
Neuroinflammation is also implicated in AD. Our data demonstrate that the endogenous
mediator of inflammation prostaglandin J2 (PGJ2) promotes APP processing by α and βsecretases in neuronal cells. Firstly, we show that PGJ2-treatment lowered full-length APP
protein levels (FL-APP) without affecting APP mRNA levels. Pretreatments with specific
inhibitors showed that the decrease in FL-APP was independent of proteasomal, lysosomal,
calpain, caspase, and γ-secretase activities. Secondly, PGJ2-treatment selectively diminished
mature but not immature FL-APP. Mature FL-APP is O and N-glycosylated, whereas immature
FL-APP is only N-glycosylated. Thirdly, PGJ2-treatment increased the overall levels of protein
O-GlcNAcylation, a form of O-glycosylation where O-linked β-N-acetylglucosamine (OGlcNAc) is linked to serines and threonines in nucleocytoplasmic protein domains. OGlcNAcylation is known to occur on APP and protect proteins from proteasomal degradation.
Fourthly, PGJ2-treatment promoted further cleavage of secreted APP, specifically sAPPα and
sAPPβ, which are generated by α and β-secretase, respectively. Notably, PGJ2-treatment induced
caspase-dependent cleavage of sAPPβ. Our results suggest that by increasing protein OGlcNAcylation levels, PGJ2 renders mature APP less prone to proteasomal degradation, thus
shunting APP toward processing by α and β-secretases. These PGJ2-induced APP glycosylation
and proteolytic mechanisms that generate various secreted N-terminal APP fragments, should be
targeted in conjunction with Aβ formation to prevent/treat AD pathophysiology linked to
neuroinflammation.
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2.2. INTRODUCTION
Neuroinflammation is actively involved in the pathogenesis and progression of AD101;136140

. Cyclooxygenases (COX -1, constitutive; COX-2, inducible) play a central role in

neuroinflammation by converting arachidonic acid into prostaglandins141;142. COX-2 is highly
induced in AD, and its increase correlates with AD severity and neuronal dysfunction101-104.
COX-1 is also actively involved in AD pathology143. Some prostaglandin (PG) products of
cyclooxygenases are neuroprotective, while others are neurotoxic144-146. In the brain,
cyclooxygenases mediate the production of prostaglandins D2, E2 and J2104;147. PGD2 is the
most abundant prostaglandin in the brain, and PGD2 increases the most under pathological
conditions147-150. Moreover, the levels and capacity to form PGD2 are significantly higher in the
frontal cortex of AD brains than in controls151. Taken together, these data support a role for
PGD2 in AD.
PGD2 is unstable, exhibiting a half-life of ~1.1 min in the brain152. PGD2 is converted to
PGJ2 by spontaneous dehydration152. PGJ2 is highly neurotoxic compared to PGE2 and
PGD2153, and PGJ2 mediates PGD2 neurotoxicity154. Furthermore, PGJ2 up-regulates COX-2
thus initiating a positive feedback loop that could have long term effects142;155. Upon brain injury
such as stroke149;156;157 and TBI97;158, the levels of free prostaglandins D2, J2 and E2 in the rodent
brain rise from almost undetectable to approximately 937 pmol/g, 37 pmol/g and 35.5 pmol/g
tissue, respectively. These in vivo PGJ2 levels in the brain represent averages and not total
amounts, as PGJ2 binds covalently to proteins through its α,β-unsaturated carbonyl group159;160.
Thus, local cellular concentrations of PGJ2 are potentially higher154. PGJ2 is also upregulated in
motor neurons of ALS patients161;162.
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PGJ2 has a short half-life so the extent of its levels in AD is unclear. However, PGJ2
induces neuronal dysfunction (reviewed in 163-165). In relation to AD, we previously showed that
in neuronal cells PGJ2 induces caspase activation and caspase-mediated cleavage of tau,
generating aggregation prone ∆TAU166;167. The latter seeds tau aggregation prior to
neurofibrillary tangle formation168-170. These data suggest that inflammation mediated by PGJ2
contributes to some aspects of AD pathology, in particular neuronal apoptosis and tau
aggregation. In current studies we investigated whether PGJ2 affects APP processing, as APP is
also relevant to AD pathology.
APP is a type I transmembrane glycoprotein with most of its full-length present in the
exoplasmic space. APP has three main isoforms, comprising 695, 751 or 770 amino acids6.
APP751 and APP770 are expressed in most tissues, and include Kunitz-type serine protease
inhibitor (KPI) and MRC Ox-2 antigen (Ox) domains6. APP695 is predominantly expressed in
neurons, and lacks the KPI/OX-2 domains3;4. APP is primarily processed (~90%) by the nonamyloidogenic α-secretase, and to a lesser extent by the amyloidogenic β-secretase171. APP
processing within the Aβ domain by α-secretase releases a free sAPPα ectodomain excluding Aβ
formation6. APP processing by β-secretase releases sAPPβ and generates a C99 fragment that is
additionally cleaved by γ-secretase to generate Aβ14. While α- and β-secretase compete for their
common APP substrate, the mechanisms regulating non-amyloidogenic and amyloidogenic
processing of APP are not well understood13.
APP plays a critical role in AD pathology as it is the precursor of Aβ that accumulates in
senile plaques and cerebrovascular amyloid deposits, which are hallmarks of the disease172. The
conditions leading to preferential amyloidogenic processing of APP resulting in Aβ
accumulation in AD, are not fully identified. Since Aβ accumulation correlates with increased
19

inflammation in AD brains138;173, we investigated how prostaglandins D2, J2 and E2 alter APP
processing in rat primary neuronal cultures and in SY5Y neuroblastoma cells overexpressing
human APP. From the three prostaglandins tested, PGJ2 induced the most significant changes by
promoting APP cleavage by α and β-secretases. We propose that the increase in overall levels of
protein O-GlcNAcylation induced by PGJ2 facilitates the access of APP to α and β-secretases
processing. Since the cyclooxygenase pathway emerged as an important determinant of the
cytotoxicity associated with neuroinflammation, our studies identified potential mechanisms that
link neuroinflammation to APP processing and AD pathophysiology.
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2.3. MATERIALS AND METHODS
2.3.1. Reagents and antibodies - Reagents and antibodies - Tissue cultures supplies from Life
Technologies (Carlsbad, CA). Prostaglandins D2, E2, J2 and the J2 analog CAY10410 from
Cayman Chemical (Ann Arbor, MI). Deglycosylation O-Glycosidase & Neuraminidase Bundle
from New England Biolabs (Ipswich, MA). Inhibitors: epoxomicin (Peptides International Inc.,
Louisville, KY); calpeptin (Z-Leu-Nle-CHO), pan caspase inhibitor (Z-VAD-FMK), β-secretase
inhibitor 2 (Z-VLL-CHO, BACE1-2) and 4 (BACE1-4), and tunicamycin from
Calbiochem/EMD Bioscience (Gibbstown, NJ); chloroquine and Brefeldin A from Sigma (St.
Louis, MO); α-secretase inhibitor TAPI-2 and γ-secretase inhibitor BMS 299897 from Santa
Cruz Biotechnology (Dallas, Tx). Primary antibodies: mouse monoclonal anti-APP (clone
22C11, 1:1000, cat# MAB348, epitope a.a. 66-81) from Millipore (Billerica, MA); mouse
monoclonal anti-CTF of APP (1:500, cat# 802801, epitope a.a. 676-695 of APP695), anti-βtubulin (1:10000, cat# MMS-435P), anti-O-GlcNAc (1:500, cat# 838004) and rabbit polyclonal
anti-sAPPβ (1:1000, cat# 813401, β-secretase-cleaved neoepitope, negligible cross reactivity to
sAPPα), anti-sAPPα (1:1000, cat# 813501, no cross reactivity to sAPPβ), and anti-βIII-tubulin
(1:1000, cat# 802001, for immunofluorescence) from BioLegend (San Diego, CA); rabbit
monoclonal anti-BACE1 (clone D10E5, 1:1000, cat# 5606), anti-calreticulin (ER maker, 1:500,
cat# 12238), and rabbit polyclonal anti-APP (1:1000, cat # 2452), from Cell Signaling
Technology (Danvers, MA); mouse monoclonal anti-β-actin (1:50000, cat# A-2228), and rabbit
polyclonal anti-β-actin (1:10000, cat# A-2066) from Sigma (St. Louis, MO); mouse monoclonal
anti-TGN38 (Golgi marker, 1:1000, cat# MA3-063, ThermoScientific, Bridgewater, NJ).
Secondary antibodies with HRP conjugate (1:10,000) from Bio-Rad Laboratories, Hercules, CA.
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2.3.2. Cell cultures – Primary cerebral cortical cultures: Dissociated cultures from Sprague
Dawley rat embryonic (E18, both sexes) cerebral cortical neurons were prepared as in 174. Cells
were plated at a density of 6X106 cells per 10 cm dish, or 2.5X105 cells per well on 24-well
plates (cell viability only). Cultures were maintained in Neurobasal media supplemented with
2% B27 and 0.5 mM L-Glutamax at 37°C in a humidified atmosphere containing 5% CO2. Half
of the medium was changed every 4 days. Experiments were performed at 7 DIV. According to
manufacturer’s specifications, Neurobasal medium contains several proprietary factors that
ensure a mostly pure (> 95%) neuronal culture; glial growth is inhibited without a need for the
anti-mitotic agent arabinofuranosyl cytidine 175;176. APP-SY5Y cells: SH-SY5Y are human
derived neuroblastoma cells with neuron-like properties. The cells used for these experiments
[APP-SY5Y, obtained from Dr. N. Robakis] were stably transfected to overexpress wild type
human APP695 as described in 177. Cultures were maintained in a 1:1 ratio ATCC-formulated
MEM growth media (Life Technologies, cat#11095-080) and F12 (Life Technologies, cat#
11765-054) supplemented with 1X Non-essential amino acids (Corning Cellgro, cat# 25-025-Cl),
1mM sodium Pyruvate (Corning Cellgro, cat# 25-000-Cl), 1.5g/L Sodium Bicarbonate (Corning,
cat# 25-035-Cl), 5% FBS (RMBI), and 1% pen/strep (Invitrogen, cat#15140-122), at 37°C in a
humidified atmosphere containing 5% CO2.
2.3.3. Culture treatments – Cortical neurons were treated acutely (4 h, 8 h, 16 h or 24 h) by
adding DMSO (vehicle control) or different drugs (dissolved in DMSO) directly to DMEM
supplemented with 0.5 mM L-Glutamax and 1 mM sodium pyruvate (all from Invitrogen) in the
absence of serum. APP-SY5Y cells were treated similarly, except that the drugs were added
directly into their respective growth medium with all the components excluding 5% FBS. The
final DMSO concentration in the medium was 0.5% for all cells.
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2.3.4. Western blotting - After treatment, cells were rinsed once with PBS and harvested by
gently scraping into ice-cold lysis buffer [20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 1 mM
EGTA, 2.5 mM Na4P2O7, 1 mM β-glycerophosphate, 50 mM NaF, 1 mM phenylmethylsulfonyl
fluoride, 1% NP40, 1 mM Na3VO4, 1% Glycerol and protease inhibitor cocktail (Sigma-Aldrich,
St Louis, MO)]. Following lysis (overnight at -80oC), cell extracts were centrifuged (19,000xg
for 10 min) at 4oC. Protein concentration of the NP40-soluble supernatants were determined with
the BCA assay. Western blot analysis was carried out following SDS-PAGE. Normalized
samples were boiled for 5 min in Laemmli buffer and loaded onto gels (10 µg to 30 µg of
protein/lane). Following electrophoresis, proteins were transferred onto an Immobilon-P
membrane (Millipore, Bedford, MA, USA). The membrane was probed with the respective
antibodies, and antigens were visualized by a standard chemiluminescent horseradish peroxidase
method with the ECL reagent. Semi-quantitative analysis of protein detection was done by
densitometry and image analysis with the ImageJ program (Rasband, W.S., ImageJ, U.S. NIH,
Maryland, http://rsb.info.nih.gov/ij/, 1997-2006).
2.3.5. Cell viability assay - Cell viability was assessed with the 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyl tetrazolium bromide (MTT) assay as described 178. MTT is reduced largely within the
cytoplasm of most cells 179;180. Although a tetrazolium-based MTT assay has been reported to
produce high variability results when using glycolysis inhibitors181, its utilization of
mitochondrial reductase enables for accurate detection of PGJ2-induced cell death. PGJ2 activity
of inhibiting complex 1 of the ETC correlates with reductions of cell viability90.
2.3.6. RT-PCR analysis –Total RNA was isolated from rat E18 cortical neurons with the
RNeasy® Mini Kit (Qiagen). Endpoint RT-PCR: RT-PCR was performed with 1µg RNA using
the Qiagen® Onestep RT-PCR Kit. The cycling parameters were: 50°C for 30 min, 95°C for 15
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min, 94°C for 1 min 63°C for 1 min, and 72°C for 2.5 min for 35 cycles using the BioRad C1000
Touch Thermal Cycler. PCR products were visualized on 2% agarose gels and quantified using
Image J. Quantitative RT-PCR (qRT-PCR): total RNA (1µg) was reverse transcribed to cDNA
with the All-in-One™ First-Strand cDNA Synthesis Kit (GeneCopoeia). The quantitative
analysis of the cDNAs was performed using the All-in-One™ qPCR Mix Kit (GeneCopoeia) in
an Applied Biosystems 7500 real-time PCR system with cycling parameters of 95°C for 15 min,
95oC for 15 sec, 63°C for 30 sec, and 72°C for 35 sec for 40 cycles. Previously described rat
primers for APP and GAPDH 182 were used for both RT-PCR analyses: APPsense (sr841): 5’GAGTCTGTGGAGGAGGTAGTCC-3’; APPantisense (αr1970): 5’CTTCTGTCTTGATGTTTGTCAACC-3’; GAPDHsense:
5’ATGGTGAAGGTCGGTGTGAACG-3’; GAPDHantisense: 5’GTTGTCATGGATGACCTTGGC-3’. For both RT-PCR analyses, PCR products were 928bp
for APP and 495bp for GAPDH. APP values were normalized to GAPDH.
2.3.7. O-Deglycosylation analysis - Total proteins (30 µg) from the NP40-soluble supernatants
obtained from the rat cortical cultures were deglycosylated at their O-glycosylation sites by Oglycosidase in conjunction with neuraminidase (New England Biolabs, cat# E0540S) following
the manufacturer's protocol. Upon completion of the assay, normalized samples were boiled for 5
min in Laemmli buffer and loaded onto gels (30 µg of protein/lane). Following SDS-PAGE,
western blot analysis was carried out as described above. The membranes were probed with
antibodies for full length APP.
2.3.8. Secreted APP (sAPP) analysis – We assess the levels of sAPPα and sAPPβ produced by
SY5Y neuroblastoma cells overexpressing APP695 (APP-SY5Y). Following the respective
treatments, the cell culture medium (8 ml) from each 10 cm dish was collected, SDS was added
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to a final concentration of 0.2%, and the media was boiled for 10 min. The conditioned
media were centrifuged at 1000xg for 2 min to remove any cell debris and then on Amicon Ultra
30K centrifugal filter devices at 3200xg for 40 min. The resulting 135 µl concentrates were
normalized for protein, and prepared for western blot analysis (20µg of protein per sample) as
described above. The membranes were probed with antibodies for sAPPα and sAPPβ.
2.3.9. Aβ 1-40 and 1-42 ELISAs - Aβ1-40 and Aβ1-42 ELISA kits were obtained from Invitrogen
and the assay was carried out according to the manufacturer’s instructions. APP-SY5Y cells
were incubated in serum-free medium with PGJ2 for 16 h, and medium was collected and
concentrated. Normalized cell lysates and conditioned media were then incubated in the ELISA
plate overnight. A horseradish peroxidase–labeled anti-rabbit antibody was added, and after a
substrate was added and the color change recorded in a spectrophotometer.
2.3.10. Immunostaining - Primary neurons were fixed with 3.7% paraformaldehyde for 30 min
at 37°C, rinsed three times with cold PBS, and incubated for 30 min in 100% methanol.
Following a rinse with cold PBS, the neurons were incubated for 30 min at room temperature
with 10% normal goat serum (NGS) and 1% bovine serum albumin (BSA) in PBS, as the
blocking buffer. Subsequently, neurons were incubated overnight at 4°C with the respective
primary antibodies diluted in blocking buffer, and washed with PBS four times (5 min each). The
neurons were then incubated for 2 h at room temperature with goat anti-mouse IgG Alexa Fluor
488 (1:1000) and goat anti-rabbit IgG Alexa Fluor 594 (1:1000) diluted in blocking buffer. After
several washes, the slides were cover slipped with Vectasheild® mounting media containing
DAPI and analyzed under a Zeiss Fluorescence Axio Imager using AxioVision Rel 4.8 software.
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For immunofluorescence quantification, exposure time per channel was kept constant
among sections. For each captured image, ZVI files were loaded onto Image J (NIH, Bethesda,
MD). Each channel was analyzed to a threshold between 1-2 standard deviations from the mean
intensity to isolate the positive signal from each image. Pixel areas meeting threshold intensity
criteria, per square micron, were measured in each image crop.
2.3.11. Statistical analysis - Statistical significance was estimated using the Student t-test or
one-way ANOVA (Tukey or Bonferroni multiple comparison test) with the Prism 6 program
(GraphPad Software, San Diego, CA).
2.4. RESULTS
2.4.1. PGJ2-treatment diminishes APP levels more effectively than PGD2 or PGE2 - There
is an association between increased cyclooxygenase activity and AD severity 103. In addition,
some non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit cyclooxygenases, seem to
decrease Aβ42 production by modulating γ-secretase activity 183. These data support the notion
that prostaglandin products of cyclooxygenases may affect APP processing. For this reason, we
compared the effects of PGJ2, D2 and E2 on APP levels upon treatment for 24h in rat primary
cortical cultures. Neuronal full-length APP was detected as three bands (Fig. 4A). The lowest
band corresponds to immature APP that is N-glycosylated within the ER, and the two highest
bands depict N- and O-glycosylated APP, with O-glycosylation taking place in the medial/trans
Golgi 184 (scheme, Fig. 4A). While 10 µM PGJ2 diminished the levels of mature (N and Oglycosylated) APP by 54%, immature (N-glycosylated) APP was decreased by less (30%). PGD2
showed a similar trend, but at higher concentrations (15 µM and 30 µM). PGE2 induced the
lowest changes of all, with 75 µM PGE2 decreasing mature APP by 34% and immature APP by
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20%, the latter not reaching significance (p = 0.09). We also included the drug CAY10410
(CAY) in our analysis to address the mechanism by which PGJ2 induces its effect. CAY is a
PGJ2 analog that binds to the PPARγ receptor but lacks the reactive cyclopentenone ring, thus it
is unable to form Michael adducts by binding covalently to proteins 185. CAY did not change any
of the APP forms, indicating that the PGJ2 effect is PPARγ-independent.
From all the conditions tested, 10 µM PGJ2 manifested the greatest neurotoxicity
inducing a 31% loss of viability, followed by 75 µM PGE2 (18% loss), while PGD2 and CAY
exhibited no significant toxicity (p > 0.2, Fig. 4B). Since PGJ2 induced the most significant
changes in APP levels and neuronal viability, we decided to focus on the effects of PGJ2 in all
subsequent experiments.
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Fig 4. PGJ2-treatment of rat cerebral cortical neurons diminishes APP levels more effectively than PGD2 or PGE2.
Neurons were treated for 24h with DMSO (vehicle, control), PGJ2 (J2, 10µM), CAY10410 (10µM, CAY, a PGJ2 analog), PGD2
(D2, 15µM and 30µM) or PGE2 (E2, 75µM). (A) - Total neuronal lysates were analyzed by western blotting (30µg of protein/lane)
probed with the respective antibodies to detect full length APP (22C11 antibody) and β-tubulin (loading control). Molecular mass
markers in kDa are shown on the right. APP levels were semi-quantified by densitometry. Data in graphs represent the
percentage of the pixel ratio for each of the three APP forms corresponding to mature (top and middle bands) and immature
(bottom band) APP over β-tubulin for each condition compared to control (100%). Values are means ± s.d. (standard deviation)
from two independent experiments. Asterisks identify the values that are significantly different from the control using Bonferroni
One Way ANOVA. FL-APP, full length APP695; N, N-glycosylated; O, O-glycosylated. (B) - Neuronal viability was assessed with
the MTT assay. Percentages represent the ratio between the data for each condition and control (100%). Values indicate means
and s.e. (standard error) from at least two independent experiments (6 determinations) per group. Asterisks identify values that
are significantly different from control Bonferroni One Way ANOVA (* p<0.05; ** p<0.01; *** p<0.001). The scheme on the right
represents membrane-bound FL-APP with its E1, E2 and Aβ domains, and its N- and O-linked glycans.
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2.4.2. PGJ2 induces a time and dose-dependent decrease in APP protein levels that
correlates with the loss of neuronal viability, but does not alter APP mRNA levels –
Treatment of rat primary neuronal cultures with 10 µM PGJ2 for 16h (Fig. 5A) induced
decreases in mature (~72%) and immature (30%) APP levels, with the former (p < 0.05) but not
the latter not (p = 0.28) being significant. Longer incubations (24h) caused a similar trend, while
shorter time points (4h and 8h) caused only minor changes (p ≥ 0.2). The time course of the loss
in cell viability caused by 10 µM PGJ2 (Fig. 5B) coincided with the decrease in APP levels, as it
was significant by 16h (31%, p = 0.001) but not at earlier time points (p > 0.9).
In terms of concentration dependence, mature APP levels (Fig. 5C) and cell viability
(Fig. 5D) were significantly diminished (p < 0.01) upon treatment with 10 µM PGJ2 for 16h.
However, PGJ2 concentrations lower than 10 µM failed to decrease the levels of mature APP
and cell viability (p > 0.12) except for 1 µM PGJ2, which showed a tendency to increase the
levels of mature APP.
The decline in APP protein levels induced by PGJ2 was not due to a decrease in APP
transcription. Endpoint RT PCR analysis revealed that 16h incubations with PGJ2 concentrations
ranging from 1 µM to 20 µM did not significantly alter gene expression of APP at the mRNA
level (p > 0.16, Fig. 5E). Quantitative RT PCR revealed that the ratio of APP mRNA/GAPDH
mRNA was not statistically different (p = 0.613) when normalized to the control value (Fig. 5E).
Together, these data show that PGJ2 selectively alters the protein levels of mature APP,
which is N and O-glycosylated, with very minor changes in immature N-glycosylated APP. The
decline in mature APP correlates with the loss of cell viability.
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Fig 5. PGJ2 induces a time and dose-dependent decrease in APP protein levels and loss of viability in rat cerebral
cortical neurons, but does not alter APP mRNA levels. Neurons were treated with 10 μM PGJ2 for different times (A
and B), or with increasing concentrations of PGJ2 (16h, C, D, and E). (A and C) - Total neuronal lysates were analyzed
by western blotting (30µg of protein/lane) probed with the respective antibodies to detect full length APP (22C11 antibody)
and β-tubulin (loading control). Molecular mass markers in kDa are shown in the center. APP levels were semi-quantified
by densitometry. Data in graphs represent the percentage of the pixel ratio for each of the three APP forms corresponding
to mature (top and middle bands) and immature (bottom band) APP over β-tubulin for each condition compared to control
(100%). Values are means ± s.e. (standard error) from four independent experiments. FL-APP, full length APP695; N, Nglycosylated; O, O-glycosylated. (B and D) - Neuronal viability was assessed with the MTT assay. Percentages represent
the ratio between the data for each condition and control (100%). Values indicate means and s.e. from at least three
independent experiments per group. Asterisks in (A) through (D) identify values that are significantly different from control
Bonferroni One Way ANOVA (* p<0.05; ** p<0.01; *** p<0.001). (E) – Total RNA isolated from the neurons was analyzed
by Endpoint (left, 2% agarose gel) and quantitative (right) RT-PCR. Percentages represent the ratio between the data for
each condition and control (100%). Values in graphs indicate means and s.e. from three independent experiments per
group. There is no significant (ns) difference from control.
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2.4.3. The decline in mature APP levels induced by PGJ2 is independent of proteasomal,
lysosomal, caspase and calpain-mediated degradation – The low levels of mature APP
detected upon PGJ2 treatment could be attributed to increased APP degradation by cellular
proteases known to affect APP levels 13;186. To address this premise, we pre-treated for 30-min
the cortical neurons with proteasomal (epoxomicin, Epox, 5 nM), calpain (calpeptin, Cpt, ZLNle-CHO, 20 µM), pan caspase (Casp, Z-VAD-FMK, 20 µM), and lysosomal (chloroquine,
CQ, 10 µM) inhibitors prior to 10 µM PGJ2 treatment (16h). As shown in Fig. 6A, none of these
protease inhibitors prevented the PGJ2-induced reduction of mature APP levels.
Mature and immature APP levels were increased by at least 60% in neuronal cultures
treated with chloroquine plus PGJ2 compared to PGJ2 alone. However, the highly specific
proteasome inhibitor epoxomicin did not significantly (p > 0.9) alter the levels of APP in control
and PGJ2-treated neuronal cultures. These data support findings that a certain percentage of the
full length APP degradation is mediated by lysosomes 187 but not by the proteasome pathway.
To investigate APP processing, we also assessed the effect of the listed protease
inhibitors on the levels of the C-terminal fragment (CTF) of APP using an antibody raised
against the last 20 residues of APP695. From all of the inhibitors, calpeptin alone or in
combination with PGJ2 was one of two inhibitors that stabilized CTF-APP (Fig. 6B).
Chloroquine by itself also stabilized CTF-APP but to a minor extent compared to calpeptin.
Notably, previous studies also reported that calpeptin increased the levels of CTF-APP,
suggesting that calpain activity regulates APP cell surface distribution 188.
Overall, these data indicate that the PGJ2-induced decline in mature APP is not mediated
by any of the proteases tested.
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Fig 6. The decline in mature APP levels induced by PGJ2 is independent of proteasomal, lysosomal, caspase and
calpain-mediated degradation in rat cerebral cortical neurons. Neurons were treated with DMSO (vehicle, control) or
PGJ2 (10 μM) alone or in combination with Epoxomicin (5 nM, Epox, proteasome inhibitor), calpeptin (20 μM, Cpt, calpain
inhibitor), pan caspase inhibitor (20 µM, Casp), and chloroquine (10 µM, CQ, lysosomal inhibitor). For comparison, neurons
were also treated with each inhibitor alone. Total neuronal lysates were analyzed by western blotting (30µg of protein/lane)
probed with the respective antibodies to detect in (A) full length APP (FL-APP, 22C11 antibody) and β-tubulin (loading
control), and in (B) full length APP and its C-terminal fragment (FL-APP, 110kDa, APP-CTF, 15kDa, with the anti-CTF
antibody) and actin (loading control). Molecular mass markers in kDa are shown in the center (A) and on the right (B). In (A)
APP levels were semi-quantified by densitometry. Data in graphs represent the percentage of the pixel ratio for each of the
three APP forms corresponding to mature (top and middle bands) and immature (bottom band) APP over β-tubulin for each
condition compared to control (100%). Values are means ± s.e. (standard error) from three independent experiments.
Asterisks identify the values that are significantly different from PGJ2-treatment alone Bonferroni One Way ANOVA (**
p<0.01; *** p<0.001). FL-APP, full length APP695; N, N-glycosylated; O, O-glycosylated; ns, non-significant.
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2.4.4. The decline in mature APP levels induced by PGJ2 is mimicked by treatment with a
β-secretase inhibitor but not by inhibitors of α or γ-secretases in rat cerebral cortical
neurons - To further address the mechanism by which PGJ2 downregulates the levels of mature
APP, we focused on the APP-processing secretases (Fig. 7A, right scheme). The neuronal
cultures were pre-treated for 30-min with β-secretase inhibitor II (Z-VLL-CHO, 1 µM), αsecretase inhibitor TAPI-2 (10 µM), or γ-secretase inhibitor BMS 299897 (GSI, 0.5 µM) prior to
the 10 µM PGJ2 treatment (16h). As shown in Fig. 7A (western and graphs), none of the
secretase inhibitors prevented the PGJ2-induced reduction in mature APP levels.
Each individual inhibitor on its own exerted different effects on FL-APP. The α-secretase
inhibitor increased all three forms of glycosylated APP (Fig. 7A) by 85% (mature, top), 49%
(mature, middle), and 31% (immature), supporting its role as the major secretase for APP
processing under non-stress conditions 171. The γ-secretase inhibitor had no significant effect on
FL-APP levels (Fig. 7A, p > 0.3), but was the only inhibitor that stabilized the C-terminal
fragment of APP (CTF-APP, Fig. 7B and left scheme in Fig. 7A). The latter result confirms the
γ-secretase function, which is to cleave within the CTF-APP, as its inhibition increases CTFAPP levels. Note that in Fig. 7A the three glycosylated forms of APP are detected because the
samples were run on a 5% gel. In Fig. 7B, the samples were run on a 4% to 20% gradient gel to
capture the 15 kDa CTF-APP, thus the FL-APP is detected as one band corresponding to its three
glycosylated forms that are not separated under these electrophoretic conditions.
Just like PGJ2, the β-secretase inhibitor significantly reduced mature (p < 0.001) but not
immature APP levels (Fig. 7A). Independently, PGJ2 and the β-secretase inhibitor decreased
mature APP to a similar extent (Fig. 7A, p > 0.6). Note that β-secretase levels per se were not
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altered by PGJ2 treatment (Fig. 7C). Because α and β-secretases can compete for the same pool
of APP as a substrate 189, it is predicted that β-secretase inhibition will increase APP cleavage by
α-secretase, thus mimicking in part the PGJ2-effect.
Based on these findings, it is clear that the decrease in mature APP induced by PGJ2 is
independent of γ-secretase activity, as its inhibitor did not prevent the decline in mature APP.
Unfortunately, we were not able to differentiate between endogenous sAPPα and sAPPβ in the
rat primary neuronal cultures conditioned media because of a lack of specific antibodies for each
of the rodent sAPP forms. To detect sAPPα and sAPPβ we conducted studies with human
neuroblastoma (SY5Y) cells that overexpress APP695, which are shown in Fig. 11.
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Fig 7. The decline in mature APP levels induced by PGJ2 is mimicked by treatment with a β-secretase inhibitor but not by inhibitors
of α or γ-secretases in rat cerebral cortical neurons. In (A and B) neurons were treated with DMSO (vehicle, control) or PGJ2 (10 μM)
alone or in combination with β-secretase inhibitor 2 (1 µM, BACE1-2), α-secretase inhibitor (10 μM, TAPI-2), or γ-secretase inhibitor (0.5 µM,
GSI). For comparison, neurons were also treated with each inhibitor alone. Total neuronal lysates were analyzed by western blotting (30µg
of protein/lane) probed with the respective antibodies to detect in (A) full length APP (FL-APP, 22C11 antibody) and β-tubulin (loading control),
and in (B) full length APP and its C-terminal fragment (FL-APP, 110kDa, APP-CTF, 15kDa, with the anti-CTF antibody) and actin (loading
control). (C) - Neurons were treated with DMSO or 10 μM PGJ2 for different times (left), or with increasing concentrations of PGJ2 (16 h,
right). Total neuronal lysates were analyzed by western blotting (30µg of protein/lane) probed with an antibody to detect β-secretase (BACE1)
and actin (loading control). In (A and C) APP levels were semi-quantified by densitometry. Data in graphs (A) represent the percentage of
the pixel ratio for each of the three APP forms corresponding to mature (top and middle bands) and immature (bottom band) APP over βtubulin for each condition compared to control (100%). Data in graphs (C) represent the percentage of the pixel ratio for BACE1 over actin
for each condition compared to control (100%). Values are means ± s.e. (standard error) from three independent experiments. Asterisks in
(A) identify the values that are significantly different from the PGJ2-treatment alone using Bonferroni One Way ANOVA, (** p<0.01; ***
p<0.001). Both schemes represent membrane-bound FL-APP with its E1, E2 and Aβ domains, and its N- and O-linked glycans. In addition,
the right scheme depicts the APP cleavage sites of the canonical (α, β, γ) secretase pathway, while the left scheme shows the APP products
generated by cleavage via the canonical secretase pathway. FL-APP, full length APP695; N, N-glycosylated; O, O-glycosylated; BACE1, βsecretase; CTF, C-terminal fragment; ns, non-significant.

35

2.4.5. PGJ2 increases the levels of O-GlcNAcylated proteins – Since the majority of APP
processing by α, β and γ-secretases occurs following O-glycosylation 184;190, we reasoned that
PGJ2 may promote APP processing by altering its level of glycosylation. We first confirmed that
the three detected forms of FL-APP corresponded to glycosylated APP. The rat primary neuronal
cultures were treated with tunicamycin (Tunic., 2 µM), which blocks protein N-linked
glycosylation 191. Although tunicamycin decreased the levels of all glycosylated FL-APP forms,
the decline was significant (p = 0.02) only for the mature (middle) band in cultures treated with
tunicamycin combined with PGJ2 (Fig. 8A). Tunicamycin causes ER stress 192, and under these
conditions APP seems to be turned over by the proteasome 193. Thus, it is not surprising that APP
levels are lower upon tunicamycin treatment than in controls.
We also treated the neuronal cultures with Brefeldin A (Bref. A, 15 µM), which
significantly (p < 0.03) raised the levels of all glycosylated FL-APP forms ranging between
131% and 188% compared to controls (Fig. 8A). These higher levels of glycosylated APP reflect
the effect of Brefeldin A, which induces the retrograde transport of Golgi proteins into the ER,
leading to their ER accumulation instead of in the Golgi 194. As Brefeldin A also blocks ER to
Golgi protein trafficking, the N-glycosylated APP is the major form detected upon Brefeldin A
treatment (Fig. 8A, lighter exposure). In addition, unglycosylated APP was obvious only in
Brefeldin A treated neurons (Fig. 8A). The higher levels of FL-APP (unglycosylated and
glycosylated) detected in Brefeldin A treated neurons than in controls, suggest that FL-APP has
no access to secretases for its processing, as it is retained in the ER.
We next incubated control and PGJ2-treated neuronal lysates with an O-deglycosylation
mix containing neuraminidase and O-glycosidase, which when used in combination remove
some but not all of the O-linked glycans from proteins 195;196. It is clear that upon enzymatic O36

deglycosylation, the top band corresponding to mature N- and O-glycosylated APP was
significantly decreased (47.4%, p = 0.037) in control neurons (Fig. 8B). A similar trend was
observed for the PGJ2-treated neurons, although not significant. In the controls, incomplete Odeglycosylation was observed as the levels of the other FL-APP forms (middle and bottom
bands) did not decline. This was expected as there are no general glycosidases that remove all Olinked glycans from proteins. Overall, our results together with published reports by others 197
confirm the O-glycosylated state of the mature FL-APP forms, and that PGJ2 decreases their
levels.
APP is modified by O-linked β-N-acetylglucosamine (O-GlcNAc) at cytoplasmic serine
and threonine residues 198. Moreover, an increase in APP O-GlcNAcylation promotes APP
stabilization and increased secretase processing, in particular by α-secretase 199. Thus, we
investigated the effect of PGJ2 on overall O-GlcNAcylation of proteins. O-GlcNAcylation is a
form of O-glycosylation that occurs in the cytoplasm and nucleus, and involves O-GlcNAc
monosaccharide units O-linked to serine or threonine residues of proteins 200. For this we used an
antibody raised against a synthetic peptide containing serine-β-O-linked N-acetylglucosamine
(Ser-O-GlcNAc) that detects Ser-O-GlcNAc and Thr-O-GlcNAc, and does not cross-react with
peptide determinants or other closely-related carbohydrate antigens (manufacturer
specifications). Our results using this antibody show that PGJ2 increased the overall levels of OGlcNAcylated proteins in a concentration-dependent manner in the rat neuronal cultures (Fig.
9A).
The increase in the levels of O-GlcNAcylated proteins induced by PGJ2 was mimicked
by treatment of the rat neuronal cultures with the proteasome inhibitor Epox (5 nM, Fig. 9B), but
not by inhibitors of BACE1 (inhibitor 2, 1 µM), calpain (Cpt, 20 µM), or lysosomes (CQ, 10
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µM). One of the functions of O-GlcNAcylation is to protect proteins from being degraded by the
proteasome 201. The finding that PGJ2 mimics the proteasome inhibitor effect by increasing the
levels of O-GlcNAcylated proteins, suggests that PGJ2 renders mature APP less prone to
proteasomal degradation. Thus, upon PGJ2-treatment, more APP is accessible to secretase
processing, resulting in lower levels of mature APP. This premise is further addressed in the
discussion. Note that it is not possible to determine the direct effect of PGJ2 on the OGlcNAcylation of APP, because APP levels are highly reduced upon PGJ2-treatment (Fig. 8A,
for example).

38

Fig 8 PGJ2-treatment does not mimic
inhibition of N or O-Glycosylation in the ER
or Golgi, in rat cerebral cortical neurons. In
(A) neurons were treated with DMSO (vehicle,
control) or PGJ2 (10 μM) alone or in
combination with tunicamycin (2 µM, Tunic, Nglycosylation inhibitor), or Brefeldin A (15 µM,
Bref. A, ER to Golgi protein transport inhibitor).
For comparison, neurons were also treated with
each inhibitor alone. In (B) neurons were
treated with DMSO (vehicle, control) or PGJ2
(10 μM) and the resulting neuronal lysates
(30µg) were then treated with DMSO or with an
O-deglycosylation
mix
containing
neuraminidase and O-glycosidase. In (A and B)
the neuronal lysates were then analyzed by
western blotting (30µg of protein/lane) probed
with the respective antibodies to detect full
length APP (FL-APP, 22C11 antibody) and βtubulin (loading control). Molecular mass
markers in kDa are shown at the right. APP
levels were semi-quantified by densitometry.
Data in graphs represent the percentage of the
pixel ratio for each of the three APP forms
corresponding to mature (top and middle
bands) and immature (bottom band) APP
(unglycosylated APP also in A) over β-tubulin
for each condition compared to control (100%).
Values are means ± s.e. (standard error) from
four (A) and three (B) independent
experiments. Asterisks identify the values that
are significantly different from the control using
Bonferroni One Way ANOVA, (* p<0.05; **
p<0.01; *** p<0.001). FL-APP, full length
APP695; N, N-glycosylated; O, O-glycosylated;
unglyc., unglycosylated APP; ns, nonsignificant.
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Fig 9. PGJ2-treatment increases the
levels of O-GlcNAcylated proteins in
rat cerebral cortical neurons. In (A)
neurons were treated with increasing
concentrations of PGJ2 for 16h. In (B)
neurons were treated with DMSO
(vehicle, control), PGJ2 (10 μM), βsecretase inhibitor 2 (1 µM, BACE1-2),
epoxomicin (5 nM, Epox, proteasome
inhibitor), calpeptin (20 μM, Cpt, calpain
inhibitor), or chloroquine (10 µM, CQ,
lysosomal inhibitor) alone. Total
neuronal lysates were analyzed by
western blotting (30µg of protein/lane)
probed with the respective antibodies to
detect O-GlcNAc and actin (loading
control). O-GlcNAcylated protein levels
were semi-quantified by densitometry.
Data in graphs represent the percentage
of the pixel ratio for the levels of OGlcNAcylated proteins (O-GlcNac/actin)
over actin for each condition compared
to control (100%). Values are means ±
s.e. (standard error) from four (A) and
three (B) independent experiments.
Asterisks identify the values that are
significantly different from the control
using Bonferroni One Way ANOVA, (*
p<0.05; ** p<0.01). O-GlcNAc, O-linked
β-N-acetylglucosamine.
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2.4.6. PGJ2 decreases APP levels in the ER and Golgi, disrupts APP trafficking, and
induces neurite dystrophy – The correct glycosylation of APP is required for its proper
processing as well as axonal sorting 202. Since PGJ2 alters APP processing, we investigated
whether PGJ2 changes APP trafficking by immunohistochemical analysis of rat primary
neuronal cultures treated with 10 µM PGJ2 for 16h. We assessed the co-localization of APP (Fig.
10, red in all panels) with TGN38, a trans-Golgi network integral membrane protein, calreticulin,
an ER resident protein, and βIII-tubulin, a neuronal marker (Fig. 10, all in green in the respective
panels). PGJ2-treatment caused a decrease in APP levels in the Golgi (Fig. 10A) and in the ER
(Fig. 10B). These results show that PGJ2 does not cause APP accumulation in these intracellular
compartments.
As we previously established 166 and is shown in Fig. 10C, dystrophic-like neurites were
detected in PGJ2-treated but not control cortical neuronal cultures. Sites of neuritic dystrophy are
indicated by bulb-like accumulations (white arrows) of APP (red) and βIII tubulin (green) in the
PGJ2-treated neurons. Higher magnifications of these structures are shown in the bottom panels
(Fig. 10D). The number of these bulb-like structures were counted and found to be significantly
higher in PGJ2-treated neurons than in controls (p = 0.0027).
These data indicate that in rat primary cortical neurons PGJ2 causes aberrant neurite dystrophy
exhibiting kinks and loops, which seem to be characteristic of AD pathology 203.
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Fig 10. PGJ2-treatment decreases APP levels in the ER and Golgi, disrupts APP trafficking, and induces neurite
dystrophy in rat cerebral cortical neurons. Neurons were treated with DMSO (vehicle, control) or PGJ2 (10 μM) for 16h
followed by immunofluorescence analyses as described under materials and methods to detect APP (22C11 and Cell
Signaling antibodies), TGN38 (Golgi marker), calreticulin (ER maker), and β-tubulin (marker for neuronal processes).
Merged images are shown in the right panels in (A) through (C). (D) shows magnified images of the areas delineated by
white boxes in (C). Arrows in (D) point to bulb-like structures within dystrophic neurites. Similar results were obtained in
duplicate (A) and triplicate (B) experiments (A, DMSO, N = 47 cells; PGJ2, N = 42 cells) and (B, DMSO, N = 69 cells;
PGJ2, N = 61 cells). Immunofluorescence was quantified in each image field using Image J as explained under materials
and methods. Values (co-localization threshold area, pixels) indicate means and s.e. from images pooled over two or three
independent experiments for each group, and normalized to time-matched DMSO (vehicle) control. Asterisks identify
values that are significantly different from control using t-test(* p< 0.05; ** p< 0.01).
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2.4.7. PGJ2 increases the levels of sAPPα and sAPPβ fragments, including sAPPβ
fragments that are generated by caspases, in human neuroblastoma SY5Y cells
overexpressing APP695 (APP-SY5Y) – APP is cleaved by α and β secretases at specific sites
in its juxtamembrane region to release sAPPα and sAPPβ, which are ~100kDa ectodomain
secreted forms of APP. We investigated the effects of PGJ2 on sAPPα and sAPPβ levels using
APP-SY5Y cells, because these neuroblastoma cells overexpress human APP by at least ~2-fold
thus facilitating their detection, and because of the availability of antibodies to specifically
differentiate between human (not rat) sAPPα and sAPPβ. The rabbit polyclonal antibodies are
selective for APP neoepitopes exposed by α or β secretase cleavages respectively, thus enabling
specific detection of sAPPα and sAPPβ with negligible cross-reactivity.
Faint detection of intact (~100kDa) sAPPα and sAPPβ were observed under control
conditions, whereas highly enriched sAPP fragments were detected upon PGJ2-treatment (Fig.
11A, dark exposure). Three major fragments at 75kDa, ~37kDa, and ~27kDa were identified
with anti-sAPPβ in PGJ2-treated neurons (Fig. 11A, left, dark and light exposures), while three
major fragments at 50kDa, 30kDa, and 20kDa were identified with anti-sAPPα (Fig. 11A, right,
dark and light exposures). None of these fragments were detected under control conditions, and
their levels were slightly altered by β-secretase (BACE1-4) and α-secretase (TAPI-2) inhibitors
(Fig. 11A).
Notably, generation of the sAPPβ fragments was caspase-dependent, as their levels were
significantly diminished by treatment with the pan-caspase inhibitor Z-VAD-FMK (Fig. 11B,
left). Formation of the sAPPα fragments was less dependent on caspase cleavage (Fig. 11B,
right). We previously demonstrated that PGJ2 induces caspase-3 activation 166;167. Together,
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these results indicate that PGJ2 treatment triggers β-secretase processing of APP to yield the
~100-kDa sAPPβ, which undergoes further caspase-dependent cleavage to yield 75kDa, 37kDa,
and 27kDa fragments. The site of this additional cleavage is unknown. However, on the basis of
fragment size, the ~37kDa fragment resembles the N-APP ~35kDa fragment generated under
trophic deprivation, and shown to bind to death receptor 6 (DR6) 204;205.
To further investigate the effects of PGJ2-treatment on APP processing, we assessed the
levels of Aβ1-40 and Aβ1-42, which are generated from APP by β and γ-secretases. Compared to
controls, PGJ2-treatment of APP-SY5Y cells did not alter the levels of Aβ1-40 and Aβ1-42 in the
cell lysates, while it decreased both in conditioned media (Fig. 11C). The latter decrease in Aβ
peptide levels could be associated with PGJ2 inducing neurite dystrophy and hindering
intracellular trafficking as shown in Fig. 10D, thus impeding Aβ secretion.
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Fig 11. PGJ2 increases the levels of sAPPα and sAPPβ fragments, including sAPPβ fragments that are
generated by caspases, in human neuroblastoma SY5Y cells overexpressing APP695 (APP-SY5Y). In (A) cells
were treated with DMSO (vehicle, control, 16h) or PGJ2 (10 μM, 16h) alone or in combination with β-secretase
inhibitor 4 (1 µM, BACE1-4) or α-secretase inhibitor (15 μM, TAPI-2). In (B) cells were treated with DMSO (vehicle,
control, 16h) or PGJ2 (10 μM, 16h) alone or in combination with the pan caspase inhibitor (20 µM, Casp). For
comparison, cells in (A) and (B) were also treated with each inhibitor alone. Conditioned media obtained as described
under materials and methods, were analyzed by western blotting (20µg of protein/lane) probed with the respective
antibodies to detect on the left sAPPβ and on the right sAPPα, and their fragments (cleaved). Molecular mass
markers in kDa are shown in the middle. sAPP levels were semi-quantified by densitometry. Data in graphs represent
the percentage of the pixel ratio for sAPPβ or sAPPα and their fragments (marked by white asterisks), for each
condition compared to control (100%). Values are means ± s.e. (standard error) from three (A) and two (B)
independent experiments. In (C) cells were treated with DMSO (vehicle, control, 16h) or PGJ2 (25µM, 16h) alone.
Cell lysates (4µg protein/sample for Aβ1-40 and 10µg protein/sample for Aβ1-42), and conditioned media (50µl from
20-fold concentrated samples) as described under materials and methods were analyzed by ELISA to assess the
levels of Aβ1-40 (left) and Aβ1-42 (right). Values (pg of the respective Aβ peptide/ml of lysate or media) are means ±
s.e. (standard error) from four independent experiments. Asterisks identify the values that are significantly different
from control using Bonferroni One Way ANOVA (A, B) and t test (C), (* p< 0.05; ** p< 0.01, *** p<0.001). sAPPβ and
sAPPα, secreted (soluble) forms of APP generated by β and α-secretases, respectively; ns, non-significant.
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2.5. DISCUSSION
The cyclooxygenase pathway is implicated in the earliest and latest stages of AD, based
on human post-mortem and epidemiology studies and in transgenic rodent models of AD 104;146.
Prostaglandins, which are products of the cyclooxygenase pathway, are the principal mediators
of CNS neuroinflammation 99. As endogenous lipid signaling molecules, prostaglandins are
generated on demand in response to a variety of triggers, and are not proactively synthesized and
stored within cells for future release 99. Understanding the mechanisms of action of
prostaglandins and how they contribute to the development of AD remains understudied. We
focused our studies on prostaglandin J2 (PGJ2) because it is a powerful inducer of neurotoxicity
compared to PGA1, D2 and E2 206.
Our data show that PGJ2 promotes processing of FL-APP by α and β-secretases in rat
E18 primary cortical cultures and in human neuroblastoma SY5Y cells overexpressing APP695
(APP-SY5Y). We demonstrate that PGJ2 induces a decrease in the levels of mature (N- and Oglycosylated) APP, does not increase the levels of unglycosylated or immature (N-glycosylated
only) APP, nor does it alter APP mRNA levels. Moreover, in the APP-SY5Y cells PGJ2
increased the levels of sAPPα and sAPPβ, the secreted forms of APP, in particular a form of
sAPPβ that is further cleaved in a caspase-dependent manner.
Processing of FL-APP by α and β-secretases is dependent on and facilitated by its Oglycosylation 184;190. This is required for FL-APP trafficking through the secretory pathway to
reach the plasma membrane 184;190. Once at the plasma membrane, most (~90%) of FL-APP is
processed by α-secretase 171, with the remaining FL-APP being re-internalized and cleaved at the
endosomal compartment, where most of the β-secretase seems to be localized 187. It is clear from
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our studies that the decrease in mature FL-APP observed upon PGJ2-treatment is not caused by
inhibition of APP O-glycosylation. On one hand, PGJ2 did not mimic the effect of Brefeldin A, a
drug that obstructs general protein O-glycosylation by preventing protein trafficking from the ER
to cis Golgi 194. In contrast to PGJ2, Brefeldin A significantly increased the levels of
unglycosylated and immature (N-glycosylated only) FL-APP. On the other hand, PGJ2 did not
elevate, instead it diminished APP levels in the ER or Golgi, as assessed by
immunohistochemistry. Thus, PGJ2 did not hinder APP trafficking from the ER to Golgi or APP
O-glycosylation.
The paradoxical findings that PGJ2 on one hand promotes processing of FL-APP, but on
the other hand decreases the levels of O-glycosylated FL-APP led us to consider the effect of
PGJ2 on overall protein O-GlcNAcylation. Protein O-GlcNAcylation involves the addition of a
single O-linked β-N-acetylglucosamine (O-GlcNAc) to the hydroxyl side chains of serine and
threonine residues within protein nucleocytoplasmic domains 207. O-GlcNAc protein
glycosylation is different from glycosylation of proteins localized extracellularly and within the
secretory pathway. Protein O-GlcNAcylation takes place in the nucleus and cytoplasm, does not
form complex sugar structures, and is a dynamic reversible process, as O-GlcNAc can be added
or removed multiple times during the protein lifetime 207. O-GlcNAcylation is often found at
serine and threonine residues within “PEST” sequences, which are associated with short-lived
proteins 208;209. Thus, one of the functions of O-GlcNAcylation is to stabilize specific proteins by
preventing their ubiquitination and hindering their proteasomal degradation 201;210.
It is possible that PGJ2 induces APP O-GlcNAcylation to regulate the proteolytic
processing of APP. This premise is supported by the following findings: firstly, APP is modified
by O-GlcNAc linked to cytoplasmic serine and threonine residues 198. Moreover, APP O48

GlcNAcylation was shown to promote APP processing by α-secretase leading to a decrease in
Aβ secretion 199. Secondly, APP can be ubiquitinated and degraded by the proteasome 211.
Thirdly, our data show that PGJ2-treatment mimicked the effect of the proteasome inhibitor
epoxomicin on increasing overall protein O-GlcNAcylation (Fig. 9B). Furthermore, epoxomicin
did not prevent FL-APP processing in PGJ2-treated cells (Fig. 6A). Based on all of these
findings we propose that, by promoting APP O-GlcNAcylation, PGJ2-treatment prevents APP
proteasomal degradation, and shunts APP to processing by α and β-secretases.
We found that PGJ2-treatment induces APP processing to a series of N-terminal
fragments detected in conditioned media. Ectodomain fragments of FL-APP can be generated by
the canonical pathway involving α and β-secretases, as well as by the non-canonical pathway that
includes δ and η-secretases as well as meprin β 212. All of these proteases generate N-terminal
fragments of different sizes and functions 212. We analyzed by western blotting, the APP Nterminal fragments in conditioned media of PGJ2-treated APP-SY5Y cells and controls. We used
antibodies that specifically detect sAPPα or sAPPβ, or fragments derived from their further
cleavage. These antibodies are specific for sAPPα or sAPPβ forms. These antibodies react with
the respective neoepitopes exposed N-terminus to the α or β-secretase cleavage sites on FL-APP,
with negligent cross-reactivity nor with FL-APP or Aβ (manufacturer’s specifications). We
observed that PGJ2-treatment induces remarkable cleavages of sAPPα and sAPPβ to a pattern of
fragments that differs between sAPPα and sAPPβ.
Significantly, the sAPPβ-derived fragments identified in conditioned media of PGJ2treated cells, were generated in a caspase-dependent manner, while not all fragments derived
from sAPPα were caspase-dependent (Fig. 11B). We and others previously demonstrated that
PGJ2-induces caspase-activation in neuroblastoma cells 161;166 and rat primary cortical neurons
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. PGJ2 metabolite 15d-PGJ2 is a potent activator of death receptor CD95/Fas 161 and a potent

sensitizer of DR5 by up-regulating its expression 213. This is important because one of the sAPPβ
fragments generated upon PGJ2-treatment resembles in size (~35kDa) the N-APP fragment
previously shown to bind to death receptor 6 (DR6) in sensory neurons 204;205. The latter N-APP
fragment is also derived from sAPPβ, and is formed in a caspase-dependent manner upon
trophic-factor deprivation 204;205. Activation of DR6 by N-APP seems to modulate synaptic
density and axonal pruning in the adult CNS, but its relation to the pathophysiology of AD
remains controversial 214;215.
We determined that Aβ1-40 levels were significantly higher than Aβ1-42 in the APP-SY5Y
lysates and conditioned media. Aβ1-40 was also found to be the most abundant Aβ isoform in
human CSF 216. Moreover, we observed a decrease in Aβ1-40 and Aβ1-42 in conditioned media of
APP-SY5Y cells treated with PGJ2. This finding is consistent with another study showing that
APP O-GlcNAcylation promotes APP processing by α-secretase leading to a decrease in Aβ
secretion 199. Unfortunately, the latter study did not address changes in sAPPβ upon APP OGlcNAcylation. The decrease in secreted Aβ1-40 and Aβ1-42 in the conditioned media of PGJ2treated cells could also be attributed to neurite dystrophy and disruption of intracellular
trafficking induced by PGJ2, as shown herein and in 166, thus impeding Aβ secretion. Notably,
the levels of CSF Aβ1-42 seem to decline over two decades prior to the first clinical signs of AD
217

.
We confirmed that PGJ2 causes neurite dystrophy in the rat primary cortical neurons, as

we previously showed 166. Upon PGJ2-treatment, APP accumulation was detected within bulblike structures located at the dystrophic neurites, indicating trafficking problems along the
neuronal processes. These swollen, bulbous-shaped (dystrophic) neurites represent one of the
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most abundant neuritic abnormalities within the brains of AD patients, and seem to be dependent
on Aβ deposition 203. A recent study reported that dystrophic neurites in AD brains are
particularly enriched in CTF-APP fragments generated by at least three of the secretases, α, β
and η 218. In our studies, the APP accumulation was detected with an antibody (22C11) that
reacts with residues 66-81 of the N-terminus of APP, recognizing immature, mature and sAPP.
Thus, the bulb-like structures within dystrophic neurites must contain different forms of APP.
Overall, we demonstrate that PGJ2 promotes APP processing by α and β-secretases, and
that stimulation of this proteolytic canonic pathway could be mediated by PGJ2-induced OGlcNAcylation known to prevent proteasomal degradation (Fig. 12). It is difficult to
stoichiometrically analyze APP metabolism, as it can be processed by so many different known
and unknown proteases. However, our studies shed light on some of the glycosylation and
proteolytic mechanisms by which neuroinflammation via PGJ2 regulates APP processing in a
manner that is relevant to AD pathophysiology. As these PGJ2-induced mechanisms give rise to
a variety of secreted N-terminal APP fragments, they should be targeted in conjunction with Aβ
formation to prevent/treat AD pathophysiology associated with neuroinflammation.
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Fig 12. Scheme depicting the effects of PGJ2 (black arrows) on FL-APP processing. Under control conditions (white
arrows), full length APP (FL-APP) can be processed via various pathways that include secretases, the ubiquitin/proteasome
pathway (UPP), cathepsins (lysosomes), calpains, and others. The secretase pathway, includes FL-APP processing by
canonical (α, β, γ) secretases to generate secreted (soluble) APP (sAPPα and sAPPβ), Aβ, and C-terminal fragments
(CTFs). The non-canonical secretase pathway involves FL-APP processing by non-canonical (δ, η) secretases and meprin
β to generate different forms of secreted (soluble) APP and C-terminal fragments (CTFs) that are not shown. Our data
suggest that upon PGJ2-treatment, which induces protein O-GlcNAcylated, a fraction of FL-APP processing (black arrows)
is shunted from proteasomal (UPP) degradation (shorter black arrow) to the canonical α and β-secretases (longer black
arrow) to give rise to higher levels of sAPPα and sAPPβ. The latter are further cleaved, in the case of sAPPβ, by caspases
to generate fragments (thinner arrows) that potentially bind to death receptors (DRs) and induce apoptosis ( ). PGJ2treatment did not alter the intracellular levels of Aβ, while it decreased the levels of secreted Aβ. The scheme depicts the
complexity of APP metabolism, rendering it difficult to analyze stoichiometrically. For simplicity, the CTF fragments are not
shown under PGJ2-treatment. O-GlcNAc, O-linked β-N-acetylglucosamine.
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3.1. ABSTRACT
The familial cases of Alzheimer’s disease (FAD) are hereditary and the disease
symptoms develop at an unusually early age. However, the onset of the disease typically
coincides with adult life, suggesting that other factors exacerbate the predisposition to develop
AD symptoms. We reasoned that neuroinflammation could be one of these factors. To address
this premise, we investigated whether PGJ2, an endogenous mediator of inflammation, would
accelerate or exacerbate AD pathology in 3xTg-AD male mice.
The 3xTg-AD mice are homozygous for three mutations linked to familial AD: APP
Swedish, TAU P301L, and presenilin 1 M146V. These mice are viable, fertile, and initially are
physically and behaviorally normal. Transgene expression is restricted to the CNS including the
hippocampus and cerebral cortex. These 3xTg-AD mice are unique in that they develop multiple
characteristics of AD pathology including age-dependent cerebral amyloidosis that precedes
tauopathy, synaptic transmission and cognitive impairment. Aβ deposition develops by 3-4
months, LTP impairment by 6 months, and tau hyperphosphorylation by 12-15 month.
To assess the effect of PGJ2 on AD progression, 3xTg-AD male mice were injected with
PGJ2 at five weeks of age, before any pathology developed. The mice received three bilateral
PGJ2 injections (16.7µg/2µl), once per week, into the right and left hippocampal CA1 regions.
We targeted the hippocampus because it is one of the principal brain regions that deteriorates in
AD. The hippocampus is also responsible for memory consolidation, storage and working
memory. To evaluate cognitive performance of the 3xTg-AD, we used the 8-arm radial maze
(RAM) up to 8 weeks after the last injection, to assess spatial learning and working memory. At
the end of the experiments, the mice were sacrificed and analyzed by immunohistochemistry to
assess changes in APP and TAU, neuronal loss (NeuN), and gliosis (Iba1 for microglia, and
GFAP for astrocytes).
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Our data revealed that PGJ2 increased Aβ deposition in the pyramidal cell layer of the
CA1 region of the hippocampus and in the cortex. In addition, PGJ2 raised glial cell
internalization of Aβ. Conversely, PGJ2 decreased Aβ deposition and glia activation in the
stratum lacunosum moleculare (SLM) layer of the CA1 and pyramidal cell layer of the CA3
region. Compared to controls, PGJ2-treated mice exhibited significant cognitive impairment as
they aged.
Our findings support the notion that neuroinflammation mediated by PGJ2 exacerbates
the progression of AD pathology in the 3xTg-AD mouse model. We propose that specifically
targeting neurotoxic prostaglandins, such as PGJ2, is a novel and effective strategy to treat ADassociated neuroinflammation with fewer side effects.
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3.2. INTRODUCTION
Familial AD (FAD) is characterized by neurodegeneration, resulting in progressive loss
of memory and visuospatial abilities, and the altering of personality and behavior. Unlike
sporadic AD, familial cases are rare (up to 6% of all cases)219 and clinical hallmarks such as
amyloid plaques and neurofibrillary tangles (NFTs) are observed in individuals younger than the
age of 60220. FAD pathology development is a consequence of gene mutations in APP (located
on chromosome 21) and γ-secretase subunit presenilin 1 (PS1, chromosome 14) and 2 (PS2,
chromosome 1)221;222. Most of these mutations result in more amyloidogenic cleavage of APP,
giving rise to more Aβ1-42223.
To date, there are 67 observed mutations in the APP gene
(http://www.molgen.ua.ac.be/ADMutations)224. Mutations in APP associated with FAD are:
Arctic (E693G), Dutch (E693Q), Florida (I716V), Indiana (V717F), Iowa (D694N), London
(V717I), and Swedish (K670N/M671L)222 (Table 2). The Swedish point mutation, which is
located next to the N- terminus of the Aβ domain, promotes β secretase cleavage in vitro and
increased brain deposition of Aβ1-42225. The Iowa and Dutch point mutations are located within

the Aβ domain and result in accelerated Aβ1-40 fibril formation in vitro226;227. Both mutations are
associated with cerebral amyloid angiopathy (CAA), with the Dutch mutation causing cerebral
hemorrhages and dementia228 and the Iowa mutation causing severe CAA, widespread NFTs, and
increased Aβ1-40 inside plaques in AD patients229. Also located within the Aβ domain, the Arctic
mutation causes APP to be less available to α-secretase230, thus promoting amyloidogenic
cleavage and increased Aβ production231 and fibril formation232 in vivo. Like the Iowa mutation,
the Arctic mutation is associated with severe CAA, NFTs, and parenchymal deposits without
brain hemorrhaging in AD patients233. The London point mutation is located within the
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transmembrane domain of APP altering γ- secretase cleavage and increasing Aβ1-42 deposition
in vitro234. In AD patients, London mutations are associated moderate CAA, increased
parenchymal amyloid deposition and NFTs235;236. The Indiana and Florida mutations are also
located within the transmembrane domain of APP. Indiana mutations are associated with mild
CAA as well as senile plaques and NFTs237. Like the London mutation, the Florida mutation
alters γ-secretase cleavage resulting in increased Aβ1-42 deposition238.
Table 2: FAD associated APP mutations

There are 39 mutations associated with PS2 and 230 with PS1 to date
(http://www.molgen.ua.ac.be/ADMutations)224. Many of the observed mutation’s pathogenic
nature is unclear. However, 50% of all FAD cases are due to PS1 and PS2 mutions239. Presenilin
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mutations impair γ-secretase cleavage increasing Aβ1-42 deposition221;239. Some of the FAD
associated presenilin mutations are seen in Table 3.
Table 3: Some FAD associated presenilin mutations240-245

Many mouse models have been generated to study the progression of FAD pathology.
The major pitfall of using AD mouse models is that mice may not be able to model such a
complex human disease. Thus, not all characteristics of the AD pathology are recapitulated in
these mouse models. For example, there are no animal models which show progressive, agedependent cell death, senile plaque and NFT development222. This suggests that mutations alone
are not enough to cause AD development. Pre-symptomatic stages must be studied to find the
pathways involved in the initiation of AD pathology. Our lab proposes that chronic
inflammation, particularly, the COX pathway and its PG products, may set the stage for AD
development. We chose to investigate our premise with the 3xTg-AD mouse model which
exhibits amyloid plaques and NFTs, two of the major molecular hallmarks of AD.
To assess whether PGJ2 exacerbates AD pathology, PGJ2 (16.7ug/2ul/week, for 3 weeks)
was bilaterally micro-infused into the CA1 hippocampal brain region of 3xTg-AD mice. The
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transgenic mouse line 3xTg-AD, has human homozygous mutant alleles for the presenilin
(Psentm1Mpm; M146V), APP Swedish mutation (APPswe; K670N and M671L), and tau (P301L)
genes246. Translation of the overexpressed genes are restricted to the CNS, mostly in the
hippocampus and cerebral cortex. In comparison to non-transgenic mice, APP and TAU levels
are approximately 6 and 7-fold higher, respectively. Aβ40 and 42 levels are also increased in
comparison to non-transgenic and hemizygous mice. AD pathology emergence is age-dependent
with amyloid deposition observed at 3-4 months, LTP impairment at 6 months, and hippocampal
hyperphosphorylated TAU deposition at 12-15 months247. We microinfused the 3xTg-AD mice
with PGJ2 at 5weeks of age, before amyloid deposition, to potentially induce early development
of AD pathology. Our findings indicate that PGJ2, an endogenous mediator of inflammation,
promotes the deposition of Aβ in the cell layer of the hippocampal CA1 region and the uptake of
Aβ by microglia and astrocytes. These molecular changes correlate with behavioral cognitive
impairment, as PGJ2 treated mice exhibited increased working and spatial memory deficits. The
characterization of AD pathology upon prolonged PGJ2 exposure provides insight on the role of
products of the cyclooxygenase pathway in disease progression.
3.3. MATERIALS AND METHODS
3.3.1. Materials - Drugs: PGJ2 (cat. # 18500, Cayman Chemical) in DMSO. The final
DMSO concentration in PBS was 17% for all microinfusions. The solutions were freshly
prepared and stored for no more than 2 h at 4°C and in the dark.
Primary antibodies: 6e10, 1:500 cat# SIG-39320, Biolegend; GFAP, 1:500 cat# AB5541,
EMD Millipore; Iba1, 1:500 cat# 019-19741, WAKO; Tau (HT7), 1:1000 cat# MN1000, Thermo
Scientific; NueN, 1:500 cat# ABN91, EMD Millipore. Secondary antibodies: Alexa Fluor 488
(1:250, cat# A11034, rabbit), Alexa Fluor 488 (1:250, cat.# A11029, mouse), Alexa Fluor 568
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(1:250, cat# A11031, mouse), Alexa Fluor 594 (1:250, cat# A11042, chicken), Alexa Fluor 488
(1:250, cat# A11039, chicken), all from Invitrogen. Vectashield® mounting medium with DAPI
(cat# H-1200, Vector Laboratories).
3.3.2. Mice - All procedures were performed in accordance with the NIH Guidelines for
the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care
and Use Committees at Hunter College.
3xTg-AD male mice: B6; 129-Psen1tm1Mpm Tg(APPSwe, tauP301L) 1Lfa/J mice from
Jackson Laboratories. Mice were singly housed on a 12h light/dark cycle with food and water
available ad libitum and were habituated for one week before treatment. Diet manipulations were
made the night before surgery to ensure completion of tasks via food motivation. Throughout the
study, mice were monitored and maintained at ≥85% original weight.
The mice were injected with PGJ2 at five weeks of age, before any pathology developed.
All mice were bilaterally microinfused into the CA1 region of the hippocampus. Each mouse
received one injection per week for 3 weeks (3 injections) with PGJ2 (16.7μg in 2µl DMSO) or
DMSO (Fig.13). After behavioral analyses, mice were anesthetized (i.p.) with ketamine (100
mg/kg) and acepromazine (3 mg/kg), and transcardially perfused with 4% paraformaldehyde in
PBS. Brains were then extracted and analyzed via immunohistochemistry.
3.3.3. Stereotaxic surgery – Surgical procedures were followed as described in our previous
study131, except that mice received bilateral injections of vehicle (DMSO) or PGJ2 into the
hippocampal CA1 sub-region. Mice were anesthetized by isoflurane inhalation (induction 2–
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2.5%, maintenance 1.5–2%) administered in 100% oxygen and placed into a stereotaxic frame
(Model 51730D, Stoelting Co., Wood Dale, IL) fitted with a gas anesthesia mask (Model 50264,
Stoelting Co.). Holes for injection were drilled in the skull at coordinates relative to bregma for
the hippocampal CA1 region: rostral-caudal -2.0mm, medial-lateral +/- 1.0mm, dorsal-ventral
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Figure 13. In vivo treatment, behavioral
analysis, and AD paradigm outline. (Top) Mice
were injected bilaterally with (16.7µg/2µl) of PGJ2
or DMSO into the CA1 region of the hippocampus.
Mice underwent radial 8-arm maze (RAM) training
for 10 weeks. All arms were baited (*) to assess
working/spatial memory. There were 3 trials/day for
9 weeks with a retention test at week 10. (Bottom)
Mice were injected at 5, 6, and 7 weeks of age
before AD symptoms and sacked at 15 weeks
(purple dot) before synaptic transmission
impairment and tau deposition. RED indicates
deficits identified from literature1.

+1.5mm, as specified by a mouse brain atlas248. A microinjection Hamilton syringe (2µl, cat. #
7002 KH) with a 25-gauge needle was slowly inserted into the brain and left in place for five
minutes to acclimate. After acclimation, 2μl of solution was infused at an injection rate of 0.2
μL/min (Quintessential stereotaxic injector, Model 53311, Stoelting Co.). The needle was left in
place an additional five minutes after the injection to ensure total dispensation of the solution.
Following the injection, the needle was slowly removed and the skull incision was closed
with monofilament absorbable sutures (cat. # 033899; Butler Schein Animal Health, Dublin,
OH). After surgery, mice were placed on a heating pad and given 0.5cc Lactated Ringer's
solution subcutaneous injection, and soft wet rodent chow for recovery. Subsequent injections
were administered using the same drill holes established from the first surgical procedure.
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3.3.4. Groups - Mice were randomly assigned to the treatment groups (either DMSO;
n=3 or PGJ2; n=4). Mice in each group received three bilateral injections (once/week for three
consecutive weeks). Both treatment groups were given injections ~11 weeks (49-77 days) before
any signs of AD pathology. Although the sample size is small, the significant changes observed
with this preliminary study will help formulate a hypothesis which can be later confirmed with a
larger study.
3.3.5. The radial 8-arm maze (RAM) – We used the RAM behavioral task to assess
short-term spatial working memory (Fig 13). Testing animals in a room with several cues, all 8
arms were baited with Maypo®, a sweetened oatmeal mash (Homestat Farm, Dublin, OH). To
perform the task, mice must utilize the environmental cues (orientation of the room) to recall
which arms were already visited. In rodent brains, the hippocampus is actively engaged during
spatial memory as well as during the memory retrieval process for working memory249. In the
3xTg-AD mice transgene expression is restricted to the CNS including the hippocampus and
cerebral cortex. Since working memory processes heavily rely on the pre-frontal cortexhippocampus system250;251, assessing aberrations in working memory is an effective way of
measuring cognitive decline.
Mice were food restricted to 85% of free-feeding weight to promote motivation for
completing the RAM task. To acclimate mice to the maze prior to training, they were placed on
the maze that was not baited for 10 min, twice a day for 2 days (shaping). Prior to working
memory assessment, all mice were shaped to the task, allowing the mice to acclimate to the maze
and cues. To shape mice to RAM, mice were placed on the maze three times with all arms
baited. Each trial lasted 10 min followed by 1h in home cage. RAM training was performed as
previously described252-254, except all 8 arms were baited with Maypo®. To avoid the use of
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internal maze cues, the maze was rotated 90°, keeping the position of the baited arms stationary
with respect to the room cues, and cleaned before each trial. Mice received 3 consecutive trials
per day lasting no more than 10 min per trial.
To prevent non-hippocampal task completion, mice were blocked from entering 3
consecutive arms (chaining). A retention test (one trial) was performed right before sacrificing.
For each treatment condition, percent correct scores for working memory performance was
calculated by dividing the number of correct arms entered by the number of arms entered.
Working memory errors occurred when the subject had re-entered an arm where the food reward
had been previously collected. For each animal the average of three trials was used to calculate
the average and standard error of the mean for the treatment group.
3.3.7. Immunohistochemistry – 7 weeks after the last microinjection, mice were
perfused, their brains removed and post-fixed overnight at 4°C, followed by cryoprotection (30%
sucrose/PBS at 4°C). Brains were sectioned in the coronal plane using a freezing microtome at a
thickness of 20µm. Tissue sections were stored at 4°C in cryoprotectant (30% glycerol and
ethylene glycol in PBS) until use. All sections were processed as non-free-floating sections for
immunohistochemical analyses. Sections were quenched to avoid auto-fluorescence with 50mM
glycine diluted in PBS containing 0.3% Triton X-100 (PBS-T) for 30min at room temperature.
Sections were then permeabilized by sequentially washing with PBS containing 0.3% Triton
three times for 5 min. Next sections were blocked with 15% BSA in 0.3% Triton X-100 solution
for 30 min followed by overnight incubation with primary antibodies in PBS containing 0.03%
Triton X-100 (PBS-T/10) at 4°C. After washing 3 times for 5 min with PBS-T/10, sections were
blocked again for 15 min at room temperature. Respective secondary antibodies were placed
with sections for 1 hour in the dark at room temperature followed by 3, 5 min PBS-T/10 washes.
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Sections then were washed again with 1x PBS before being mounted on gelatin-subbed glass
slides using Vectasheild® Mounting medium (H-1200).
3.3.8. Quantification –Immunohistochemistry analysis: Under a wide-field fluorescence
microscope (Zeiss AxioImager) the software AxioVision was used to capture whole
hippocampal region mosaics (MosaiX capture mode, 20x magnification). Exposure time for each
channel was kept constant between sections. For each captured image, ZVI files were loaded
onto Image J (NIH, Bethesda, MD). Hippocampal and cortex subfields were isolated, cropped,
and saved as .tif files for use in intensity and co-localization analyses. Each channel was
analyzed to a threshold between 1-2 standard deviations from the mean intensity to isolate the
positive signal from each image255. Pixel areas meeting threshold intensity criteria, per square
micron, were measured in each image crop.
3.3.9. Statistics. All data are expressed as the mean ± SEM. Statistical analyses were
performed with GraphPad Prism 6 (GraphPad Software, San Diego, CA). P values of ≤ 0.05 was
considered statistically significant. For group comparisons, we performed one-way or two-way
analysis of variance (ANOVA) followed by post hoc Bonferroni tests for multiple comparisons
and t-test for single comparison.
3.4. RESULTS
3.4.1. PGJ2 induces premature spatial learning and working memory deficits in 3xTg-AD
mice
The 3xTg-AD mice exhibit cognitive decline correlating with intraneuronal Aβ
deposition at around 4 months247. To assess whether PGJ2 can induce premature Aβ
accumulation and cognitive impairment, we injected the mice at 5 weeks of age (15 weeks before
amyloid deposition). We observed that PGJ2-treated 3xTg-AD mice exhibited significantly
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increased working memory errors in comparison to DMSO-treated mice, starting at 11 weeks of
age, which corresponds to 6-weeks post first injection (Fig14 B).
The percent correct working memory calculations were based on the number of correct
entries made divided by the number of arms entered. Working memory percentage is represented
in two categories, percent correct for the first four and second four arms. Both treatment groups
made similar numbers of errors collecting the food reward from arms 1 to 4 with percent correct
arm entry between 80 and 100% (Fig 14A). However, collecting the food rewards from arms 5
through 8 proved to be a more difficult task as expected since the working memory load is
higher, resulting in PGJ2-treated animals making more working memory errors. The increased
working memory errors correspond to lower percent correct arm entries, with significant
differences seen at 6, 7, 8, and 10-week post the first injection of PGJ2. This suggests that PGJ2
hindered the formation of spatial memories regulated by the hippocampus, indicative of
cognitive impairment.
Behavioral analysis also showed that PGJ2 diminished the ability to complete the task,
correlating with the working memory errors made. (Fig 14 C and D). PGJ2-treated mice had
longer latency scores to collect all 8-baits and reached a lower asymptotic performance score
compared to controls. The use of spatial cues to determine which arm has not been entered is
regulated by the hippocampus. Mice not utilizing the spatial cues, but systematically entering
each consecutive numbered arm regardless if the food reward was taken, is indicative of
hippocampal impairment involving a chaining strategy. PGJ2-treated mice significantly
performed more episodes of chaining in comparison to DMSO treated mice (Fig 17 D).
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Fig 14. PGJ2 exacerbates spatial learning deficits in 3xTg mice. (A) 3xTg-AD mice (DMSO or PGJ2-treated)
did not exhibit impaired spatial learning assessed by mice collecting food from arms 1-4 (F (1, 44) = 0.7468, p=.392).
(B) PGJ2-treated mice show a significant overall effect of training [F (1, 45) = 10.46 p =.002]. Post hoc analysis for
post-injection weeks 6, 7, 8, and 10 showed significant differences between DMSO and PGJ2-treated mice (*p <
0.05, **p < 0.01). (C) The average time completion of RAM was significantly higher in PGJ2-treated than in control
mice [F (1, 45) = 8.454 p=.006]. (D) RAM chaining was prominent with PGJ2-treated compared to control mice [F
(1, 40) = 4.689 p=.036]. Post hoc analysis for 5 weeks post first PGJ2-injection showed significance (*p < 0.05).
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3.4.2. PGJ2 induces changes in pyramidal cell layer Aβ deposition and microglia Aβ
internalization in the CA1 and CA3 regions of the hippocampus
Aβ deposition: We performed immunohistochemistry analysis to assess whether PGJ2
exacerbated the pathological hallmarks of AD in the brain. We assessed Aβ deposition with the
6e10 antibody, which reacts with amino acid residue 3-8 of Aβ as well as APP. In general, 3xTgAD mice exhibit Aβ deposition in the CNS around 4 months of age. Animals were sacrificed at
15 weeks of age. We expected DMSO-treated mice to exhibit some Aβ deposition at this age.
However, if PGJ2 induced premature Aβ deposition, we should observe higher levels of Aβ
deposition in PGJ2-treated mice than in DMSO-treated mice. Accordingly, we observed a
significant higher accumulation of small particle and large particles of Aβ in the CA1 region of
the hippocampus of PGJ2-treated mice than in DMSO controls (Fig. 15 A and B). Conversely,
we observed less Aβ deposition within the cell layer of the CA3 region (p= 0.026, Fig 15 B and
C).
Microglia Aβ internalization: We previously showed microglia activation in the
substantia nigra of PGJ2-treated mice256. Therefore, we assessed whether PGJ2 had a similar
effect in the hippocampus. Microglia activation was assessed with the anti-Iba1 antibody. The
levels of hippocampal microglia were not significantly changed upon PGJ2-treatment of 3xTgAD mice (p= 0.416, not shown). However, co-localization experiments showed a significant
increase of internalized Aβ within activated microglia (p= 0.0077, Fig 15 B and C) in the CA1
cell layer but not the CA3.
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Neuronal TAU deposition: Immunostaining for TAU with the HT7 antibody,
showed insignificant changes between PGJ2-treated and control (p= 0.456, not shown). No
changes in NeuN staining indicate that there was no cell death (p= 0.490, not shown)
Together, this data suggests that PGJ2 impairs the amyloid clearance mechanisms in
neurons and microglia of the CA1 pyramidal cell layer region.
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Fig. 15 - PGJ2 induces changes in pyramidal cell layer Aβ deposition and microglia Aβ internalization in the
CA1 and CA3 regions of the hippocampus. (A) Immunohistochemical analysis with antibodies 6e10 (Aβ, red) and
Iba1 (microglia, green) in the hippocampal CA1 and CA3 cell layer in mice treated with DMSO (N=3) and PGJ2
(N=4). Two sections per mouse were analyzed (representative image scale: 500µm). (B) Magnified ROI from the
cell layer of hippocampal CA1 and CA3 regions (scale: 50µm, 25µm). (C) Quantification of 6e10 and Iba1
immunostaining compared by one tailed unpaired t-test. PGJ2-treated mice have increased small (p= 0.040) and
large (p= 0.034) intracellular Aβ particles within the CA1 cell layer and decreased small particle Aβ deposition in the
CA3 cell layer (p= 0.026). Co-localization immunostaining shows that microglia have increased internalized Aβ
(yellow) in the CA1 region (p= 0.0077) and less in the CA3 region (p= 0.002) in PGJ2.

3.4.3. PGJ2 induces Aβ uptake by astrocytes in the hippocampal CA1 region
We assessed whether astrocyte activation was altered in the hippocampus of PGJ2-treated
mice compared to controls. Astrocyte activation was assessed with the GFAP antibody. PGJ2 did
not significantly change astrocyte activation (p= 0.062, not shown). However, co-localization
experiments show increased levels of intracellular Aβ within astrocytes located in the cell layer
of the CA1 hippocampal region (p= 0.036, Fig 16). No significant change was observed in the
CA3 cell layer (p= 0.308, not shown).
Overall these data suggest that PGJ2 exacerbates Aβ deposition and its internalization by
local glial cells.
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Fig 16. PGJ2 induces Aβ uptake by astrocytes in the hippocampal CA1 region. Immunohistochemical
analysis with antibodies 6e10 (Aβ, red) and GFAP (astrocytes, green) for co-localization in the cell layer of
the hippocampal CA1 region in mice treated with DMSO (N=3) and PGJ2 (N=4). Two sections per mouse
were analyzed. Magnified ROI representative image scale: 50µm. One tailed unpaired t-test showed
significant increase of co-localization of Aβ and GFAP (yellow) in PGJ2-treated animals (p= 0.036).
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3.4.4. PGJ2 induces changes in Aβ deposition in the stratum lacunosum moleculare of the
hippocampal CA1 region
The post-synaptic terminals of the neurons within the pyramidal cell layer of the CA1
region associate with glutamatergic neurons in the stratum lacunosum moleculare (SLM) of the
entorhinal cortex, which is the earliest area affected in AD257. The entorhinal cortex is a main
pathway into area CA1 which is responsible for relational information processing and logical
reasoning258. Thus, if PGJ2 promotes AD pathology, we expect to see some changes within the
SLM. Immunostaining for TAU with the HT7 antibody, showed insignificant changes between
PGJ2-treated and control (p= 0.265, not shown). No changes in NeuN staining indicate that there
was no cell death (p= 0.176, not shown). Immunostaining for Aβ deposition with the 6e10
antibody, showed that the fluorescence intensity of small and large Aβ particles inside the SLM
of PGJ2-treated mice was decreased by half, compared to controls (Fig 17). These lower levels
correspond with fewer microglia in this layer (p = 0.009, Fig 17 B). Co-localization studies
confirmed that microglia exhibit less internalized Aβ (p= 0.024). The levels of activated
astrocytes and astrocyte Aβ internalization in this region of the hippocampus did not
significantly change (p= 0.240, p= 0.330, respectively, not shown).
This data suggests that PGJ2 may affect the SLM by decreasing glial levels or preventing
their activation and ability to remove Aβ deposits.
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Fig 17. PGJ2 induces changes in Aβ deposition in the stratum lacunosum moleculare of the hippocampal
CA1 region. (A) Immunohistochemical analysis with antibodies 6e10 (Aβ, red) and Iba1 (microglia, green) in the
SLM layer of the hippocampal CA1 region in mice treated with DMSO (N=3) or PGJ2 (N=4). Two sections per
mouse were analyzed (representative image scale: 100µm, merged scale: 10µm). (B) Quantification of 6e10 and
Iba1 immunostaining by one tailed unpaired t-test. PGJ2-treated mice have decreased numbers of small (p=
0.014) and large (p= 0.038) intracellular Aβ particles within the hippocampal CA1 SLM layer. PGJ2-treatment
decreased overall levels of microglia in the SLM (p= 0.009). Co-localization experiments show that microglia have
decreased internalized Aβ (yellow) in the CA1 region (p= 0.024).
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3.4.5. PGJ2 alters the levels of glial cells in the stratum oriens of the hippocampal CA1
region
We determined the amyloid burden within the stratum oriens layer of the hippocampal CA1
region. We observed no significant changes in Aβ deposition between DMSO and PGJ2-treated
mice. However, PGJ2-treated mice had ~1.24 times more activated astrocytes in the stratum
oriens than control animals (Fig 18). This data suggest that PGJ2 promoted astrocyte activation
at the site of injury. The astrocyte increase corresponded to a ~2.5-fold rise in Aβ internalization
by the astrocytes (Fig 18 B).
Immunostaining for TAU showed insignificant changes between PGJ2-treated and control
(p= 0.156, not shown). No changes in NeuN staining indicate that there was no cell death (p=
0.067, not shown).
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Fig 18. PGJ2 increased Aβ deposition in the astrocytes of the stratum oriens of the hippocampal CA1
region. (A) Immunohistochemical analysis with antibodies 6e10 (Aβ, red) and GFAP (astrocytes, green) in the
oriens layer of the hippocampal CA1 region in mice treated with DMSO (N=3) or PGJ2 (N=4). Two sections per
animal were analyzed (representative image scale: 100µm, merged scale: 50µm). (B) Quantification of 6e10
and GFAP immunostaining was analyzed by one tailed unpaired t-test. There was no significant change in
amyloid accumulation. PGJ2 animals have increased levels of astrocytes (p= 0.028). Co-localization
experiments show that astrocytes have increased internalized Aβ (yellow) in the oriens layer (p= 0.026).

Conversely, microglia levels in the stratum oriens decreased in PGJ2-treated mice and
their microglia exhibited lower levels of internalized Aβ, in comparison to control (Fig 19).
However, we expected microglia to have increased internalized Aβ in PGJ2-treated animals.
This data is interesting because microglia are known to be activated before astrocytes in AD259.
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A microglia-astrocyte cross talk has been postulated by previous studies showing that astrocytes
can reduce microglia activation via signaling through transforming growth factor TGF-β259.

Fig 19. PGJ2 decreases the levels and Aβ internalization of microglia in stratum oriens. (Top)
Immunohistochemical analysis with antibodies 6e10 (Aβ, red) and Iba1 (microglia, green) in the oriens layer of
the hippocampal CA1 region in mice treated with DMSO (N=3) or PGJ2 (N=4). Two sections per animal were
analyzed (image scale: 100µm). (Bottom) Quantification of 6e10 and Iba1 immunostaining was analyzed by
one tailed unpaired t-test. Co-localization experiments show that PGJ2-treated mice have lower levels of
intracellular Aβ in microglia (p= 0.030).
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3.4.6. PGJ2-treatment increased Aβ deposition in the cerebral cortex
The 3xTg-AD mice develop intraneuronal amyloid deposits in the hippocampus and
cortex by 4 months of age and extracellular deposits by 12 months of age247. To assess how PGJ2
affects the development of AD pathology in the cerebral cortex, Aβ, microglia, and astrocyte
levels were assessed by immunohistochemical analysis of the cerebral cortex area above the
hippocampus within the coronal section. The data show that compared to controls, PGJ2-treated
mice exhibited increased levels of small (p <.001) and large (p = 0.036) Aβ particles within the
cortex (Fig 20). Co-localization analysis demonstrated microglia (1.5-fold, Fig. 20) and
astrocytes (2-fold, Fig. 21) to have higher levels of internalized Aβ.
Immunostaining for TAU with the HT7 antibody, showed insignificant changes between
PGJ2-treated and control (p= 0.161, not shown). No changes in NeuN staining indicate that there
was no cell death (p= 0.393, not shown).
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Fig 20. PGJ2-treatment increased Aβ deposition in the cerebral cortex and microglia. (A)
Immunohistochemical analysis with antibodies 6e10 (Aβ, red) and Iba1 (microglia, green) in the cerebral cortex
of DMSO (N=3) or PGJ2 (N=4) treated mice. Two sections per mouse were analyzed (representative image
scale: 500µm, merged scale: 100µm). (B) Quantification of 6e10 and Iba1 immunostaining analyzed by one
tailed unpaired t-test. PGJ2- treated animals have increased levels of small (p= <.001) and large (p= 0.036)
Aβ particles. Co-localization analysis shows that microglia have increased internalized Aβ in the cortex (p=
0.033).
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Fig 21. PGJ2-treatment increases astrocyte Aβ internalization. Immunohistochemical analysis with
antibodies 6e10 (Aβ, red) and GFAP (astrocytes, green) in the cerebral cortex of DMSO (N=3) or PGJ2 (N=4)
treated mice. Two sections per mouse were analyzed (representative image scale: 100µm). (Right)
Quantification of 6e10 and GFAP immunostaining co-localization was analyzed by one tailed unpaired t-test.
PGJ2- treated mice exhibit increased levels of microglia with internalized Aβ in the cortex (p= 0.043). Asterisks

3.5. DISCUSSION
AD patients experience multifaceted cognitive impairment such as progressive memory
loss, attention deficits, visuospatial deterioration, and working memory deficits. This cognitive
impairment correlates with progressive neurodegeneration and cell death, typically starting from
the entorhinal cortex, spreading to the hippocampus and the rest of the brain260. The
hippocampus is responsible for the creation, consolidation and maintenance of memories. ADrelevant memory loss can be recapitulated in animal models such as the 3xTg-AD mouse model
that exhibits AD hallmarks in an age dependent manner. Although 3xTg-AD mice have the
genetic mutations associated with familial AD, the AD-pathology that these mice develop also
recapitulates the pathology observed in non-familial AD cases.
By focusing on the early stages of the development of AD pathology in the 3xTg-AD
mice, we demonstrated that PGJ2 per se, induces premature Aβ deposition and internalization,
exacerbating some aspects of AD pathogenesis. Our studies support the notion that the
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cyclooxygenase pathway mediated by PGJ2 can play an important role in the initiation and
progression of AD pathology261-263.
Our studies focus on PGJ2, the precursor of which, PGD2, is the most abundant
prostaglandin in the CNS148;160. Spontaneous dehydration of PGD2 into PGJ2 occurs during
brain injury and increases significantly in rodents from almost undetectable to the 100nM range
after stroke and TBI, which are known risk factors for AD124;264. Previous in vitro studies from
our group showed PGJ2 to be neurotoxic, more so than other prostaglandins like PGE2, PGA1
and PGD2126. In addition, our previous in vivo studies demonstrated that microinfusing PGJ2
into the substantia nigra of wild type mice, induces PD-like pathology, recapitulating motor
deficits, loss of dopaminergic neurons, and intracellular ubiquitinated protein aggregates131;256.
Using a similar approach, we microinfused PGJ2 into CA1 hippocampal region of 3xTg mice to
investigate the role of the cyclooxygenase pathway on AD pathogenesis.
We monitored in 3xTg-AD mice the progression of AD-relevant cognitive decline with
RAM behavioral assessment, as well as AD-relevant cellular changes with
immunohistochemistry. Our data demonstrate that PGJ2 impairs working and spatial memory
prematurely, compared to control DMSO-treated 3xTg-AD mice. These cognitive deficits
correspond with exacerbated intracellular microglia and astrocyte Aβ deposition in the pyramidal
cell layer of the hippocampus and in the cortex.
In contrast, PGJ2 decreased intracellular amyloid accumulation within the CA3
pyramidal cell layer and SLM of the CA1 region. Glial activity in these regions were decreased,
with less Aβ internalized by microglia and astrocytes. These findings indicate that PGJ2 affects
the hippocampal regions differently. The premature cellular changes that we detected upon
PGJ2-treatment would explain the behavioral deficits observed in the PGJ2-treated mice at 11
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weeks of age which was approximately 9 weeks prior to the documented Aβ depositionassociated with cognitive impairment1;265. This phenomenon was previously observed in chapter
2, where PGJ2 treatment of SY5Y-APP cells resulted in less intracellular levels of Aβ1-40 and
Aβ1-42. Clinical studies have also shown that a decrease in CSF Aβ42 levels is an early event in
AD progression216. Most likely due to the young age of the 3xTg-AD mice at the end of our
study, TAU deposits and neuronal loss were not detected.
In conclusion, we demonstrate that repeated infusions of PGJ2 into the hippocampal CA1
region of 3xTg-AD mice to mimic in part chronic inflammation, induce a slow-onset of AD-like
cognitive deficits, as well as glial activation. The persistent PGJ2-induced microglia activation, if
not halted, could lead to chronic inflammation with long-term effects resulting in gradual
neurodegeneration, like in AD. It is clear that brain injury, in this case initiated by a neurotoxic
product of inflammation, involves integrated signaling across neurons and microglia. Ideally,
therapeutic interventions should target all cells involved, regardless of cell type, i.e. neurons and
glia. Developing successful anti-inflammatory drugs that potentially target prostaglandin
signaling downstream of cyclooxygenases, could lead to early remediation therapies designed to
provide overall neuronal and glial benefits for patients with AD.
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CHAPTER IV

CONCLUSIONS
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There is great need to understand the mechanisms which not only cause AD but
perpetuate it. Our lab proposes that chronic inflammation sets the stage for AD development and
progression. Epidemiological studies show that inhibiting COXs with non-steroidal antiinflammatory drugs (NSAIDs) would be an effective strategy to ameliorate the effects caused by
chronic inflammation135. However, NSAIDs prevent the production of beneficial and neurotoxic
PGs which can result in stroke266;267 and cardiovascular impairment268. Our goal is to elucidate
some of the underlying AD-relevant mechanisms induced by neuroinflammation to find a more
downstream therapeutic target. It has been proposed that prostaglandins (PGs), such as PGJ2, are
important mediators of the transition from acute to chronic inflammation. However, the roles of
PGs, the major products of the COX pathway, in AD is poorly understood.
Studies have shown that Aβ, the best well-characterized toxic product of APP processing,
causes much damage including overall neuronal dysfunction, cell death, and induction of other
AD hallmarks such as NFTs. Although APP processing has been extensively investigated, the
mechanisms underlying the switch from the amyloidogenic to the non-amyloidogenic pathway
are not well understood. Our studies support the notion that products of neuroinflammation such
as PGJ2 may play a role in this transition in APP processing.
Our results from rat E18 cortical neuronal cultures demonstrate that PGJ2 alters APP
processing. PGJ2 induces a decline in APP protein levels that is independent of proteasomal,
lysosomal, calpain, caspase, α- and γ-secretase activities, as pretreatment with the respective
protease inhibitors did not prevent the PGJ2-induced APP processing. PGJ2 treatment
selectively diminishes mature (O and N-glycosylated) APP levels, but not immature (Nglycosylated) APP levels. However, this decline in mature APP is accompanied by an increase in
the levels of protein O-GlcNAcylation, a form of O-glycosylation that occurs in the cytoplasm
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and nucleus. It is well established that APP is O-GlcNAcylated, and that O-GlcNAcylation
protects proteins from being degraded by the proteasome. Thus, we hypothesize that the PGJ2induced increase in protein O-GlcNAcylation may render mature APP less prone to proteasomal
degradation, and more accessible to BACE1 processing, resulting in lower levels of mature APP.
Within SH-SY5Y neuroblastoma cells over-expressing human APP695, PGJ2 treatment raises
the levels of secreted APP (sAPP), specifically sAPPβ generated by BACE1. Moreover,
inhibiting BACE1 diminishes PGJ2-induced sAPPβ formation and additional cleavage. Based on
these results, we propose that by raising the levels of protein O-GlcNAcylation, PGJ2 facilitates
the access of APP to BACE1, thus promoting APP processing.
Based on our studies, we hypothesized that chronic inflammation perpetuates and
accelerates AD pathology promoting the development of typical AD hallmarks such as amyloid
plaques and NFTs in vivo. We observed that PGJ2 promotes motor deficits and aberrant protein
accumulation in the brain131;256 as well as cognitive decline in an age dependent manner
(unpublished) depending where PGJ2 was stererotaxically microinjected. Next we assessed
whether mechanisms initiated by PGJ2 can exacerbate AD pathology, speeding up pathology
development. PGJ2 (16.7μg in 2µl/week, for 3 weeks) was bilaterally microinfused into the CA1
hippocampal region of 5 week 3xTg mice, before any presence of AD pathology. Microinjection
of PGJ2 into the CA1 region resulted in altered Aβ deposits throughout the hippocampus as well
as glial presence and activity. These molecular changes corresponded with working/spatial
memory progressive impairment. These findings suggest that the COX pathway exacerbates the
development of AD and that PGJ2 pathways would be an effective therapeutic target. By
targeting PG pathways, the toxic side effects, like stoke and cardiovascular impairment, would
be avoided. Our preliminary in vivo results are promising, but these experiments need to be
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repeated on a larger scale and the profile of PGs generated within the CNS, measured (see Future
Directions). By assessing other mechanisms of PGJ2 within an age-dependent AD model, we
could find more viable therapeutic targets relevant to all neurodegenerative diseases in which
chronic inflammation plays a role.
In conclusion, for therapeutic treatment to have a better chance of preventing, mitigating,
or even curing AD, it is important to determine the initiator of this course of neurodegeneration.
Evaluating the relationship between PGJ2 and AD-relevant molecular hallmarks will expose
signaling pathways that best serve as a target for therapeutic intervention in AD.
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CHAPTER V

FUTURE DIRECTIONS
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AD is characterized by an increase of amyloid plaques, neurofibrillary tangles, and
production of toxic metabolites that result in progressive neuronal death and cognitive decline.
Neurodegeneration is the primary pathological feature of chronic inflammation269. Increased
levels of inflammatory PGs present within the CSF and brain parenchyma are associated with the
initial asymptomatic latent disease phase270 and the advanced later stages of AD. Thus, the use of
anti-inflammatory pharmacotherapy, such as NSAIDs, have been proposed to help treat
neurodegenerative diseases such as AD. Epidemiological studies have shown NSAIDs to be
neuroprotective, with a decreased prevalence of AD271. However clinical trials have had limited
success. One possible explanation is due to time of intervention. Prophylactic NSAID
administration before AD symptoms occur may prove more effective. However, prolonged use
of NSAIDs were shown to induce serious side effects266;268;272. Therefore, there is a great need to
find a more effective and less toxic alternative.
We propose that targeting and inhibiting the downstream pathways induced by PGs
would be a far less toxic approach. Targeting the cyclooxygenase pathway downstream of
cyclooxygenases has proven to be difficult due to reduced knowledge on the role PGs during AD
pathology. Our studies have elucidated the potential roles of PGJ2 in neurodegeneration, but
more needs to be done to determine which component of the PG pathways can be targeted for
preventative or therapeutic intervention99.
Characterizing the effect PGJ2 has on APP processing has proven to be difficult due to
the ability of APP to be cleaved by many enzymes. Our data has shown that PGJ2 increases the
levels of O-GlcNAcylation of proteins within the nucleocytoplasm compartment, which could
promote the movement of APP to BACE1 containing vesicles. Once inside the vesicles, APP is
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cleaved via the amyloidogenic pathway as well as caspases to produce a fragment that possibly
may be involved in the death receptor pathway.
To determine which components of the prostaglandin signaling pathway is a possible
therapeutic target, we propose the following:
1. Investigate the effect of PGJ2 on O-GlcNAc transferase (OGT) and OGlcNAcase (OGA) – PGJ2 may increase cytoplasmic O-GlcNAcylation by altering the balance
between the addition of O-GlcNAc (OGT) and removal (OGA). PGJ2 could upregulate or
promote OGT activity, causing more APP to be modified and internalized, or inhibit or
downregulate OGA, resulting in stabilization of O-GlcNAc-APP.
AD patients exhibit an imbalance of O-GlcNAc homeostasis. An increase of Oglycosylated proteins is detected in amyloid plaques and neurofibrillary tangles43 and hyper-OGlcNAcylation is associated with prolonged NF-κB activity and apoptosis273. OGT and OGA
levels can be assessed by western blot analysis. OGT activity can be assessed by pre-incubation
of purified OGT with PGJ2 along with an assay such as UDP-Glo™ Glycosyltransferase Assay
(Promega). siRNA experiments silencing the activity of OGT can be performed to determine
whether the effect of PGJ2 can be prevented or reversed. OGA activity can be assessed by
treating rat E18 cortical neuronal cultures with OGA inhibitor Thiamet G and comparing the
results to PGJ2 treatment.
2. Assess how PGJ2 affects APP trafficking by identifying whether anterograde or
retrograde transport is affected – Our data demonstrates PGJ2 to alter APP transport based on
immunocytochemistry data. To target APP movement to BACE1 vesicles, the type of transport
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that PGJ2 alters needs to be identified. Kymographs can be used to determine whether
anterograde or retrograde transport is affected.

3. Characterize how PGJ2 affects APP levels at particular compartments
throughout the cell – Knowing the location of the largest pool of APP under PGJ2 treatment
will give us an idea of where to start focusing therapeutic efforts. Our studies show that PGJ2
decreases total amount of APP with rat E18 cortical neurons. However, APP levels at various
cellular compartments may differ. For example, APP at the post-synaptic terminals may have
different levels than those located in the TGN. To assess these changes in levels, cell
fractionation approaches can be applied to examine APP distribution at the cellular membrane,
cytoplasm, and post-synaptic terminals.

4. Characterize the mechanisms by which PGJ2 induces AD-relevant
neuropathology – PGJ2 can initially exert its effects within neurons by freely diffusing across
the cell membrane, passing through a PG transporter or acting on G protein-coupled receptors163.
Once inside the cell, PGJ2 can associate with the peroxisome proliferation receptor (PPARγ)
located within the nucleus and affect transcription. Rat E18 cortical neuronal cultures would be
treated with drugs that target PGJ2-dependent receptor activation such as DP1 and DP2 receptor
antagonists, and a PPARγ agonist. Treatments with the DP1 or DP2 antagonists alone or in
combination with PGJ2, will evaluate if the effects induced by PGJ2 are mediated by its binding
to these receptors. While DP1 activation increases cyclic adenosine monophosphate (cAMP) and
is associated with neuroprotection, DP2 activation decreases cAMP, increases calcium and is
associated with neurodegeneration274-276. To assess PGJ2 covalent modification effects, cells
would be treated with the analog CAY10410 that cannot form Michael adducts.
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5. Characterize effects of PGJ2 on AD-like neuropathology– Our in vivo data with
the 3xTg-AD mouse open up new avenues of research. Future studies should include male and
female 3xTg mice where PGJ2 will be microinjected into the hippocampus at 3 months. To
assess AD pathology severity, mice will be analyzed at 6 months and 12-15 months of age to
correlate memory deficits with changes in cognitive memory, Aβ, and neurofibrillary tangles.
Treating and analyzing at a later point will enable the mice to develop a full spectrum of agedependent AD pathologies. Immunohistochemistry and behavioral analysis will be performed as
previously described. In corroboration with the behavioral analysis, Cox-Golgi staining will be
carried-out to assess the morphological changes in the types of spines along the dendrites.
Western blots analysis will assess levels of COX-2, ubiquitinated proteins, changes in
glycosylated full-length APP and tau cleavage. To assess the PG profile after PGJ2 treatment,
samples will be analyzed via mass spectrometry.
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